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Background: The National Institute for Health and Care Excellence (NICE) guidelines highlighted the need
for ‘large, high-quality prospective studies comparing the various methods of measuring proteinuria in
women with new-onset hypertensive disorders during pregnancy’.
Objectives: The primary objective was to evaluate quantitative assessments of spot protein–creatinine
ratio (SPCR) and spot albumin–creatinine ratio (SACR) in predicting severe pre-eclampsia (PE) compared
with 24-hour urine protein measurement. The secondary objectives were to investigate interlaboratory
assay variation, to evaluate SPCR and SACR thresholds in predicting adverse maternal and fetal outcomes
and to assess the cost-effectiveness of these models.
Design: This was a prospective diagnostic accuracy cohort study, with decision-analytic modelling and a
cost-effectiveness analysis.
Setting: The setting was 36 obstetric units in England, UK.
Participants: Pregnant women (aged ≥ 16 years), who were at > 20 weeks’ gestation with confirmed
gestational hypertension and trace or more proteinuria on an automated dipstick urinalysis.
Interventions: Women provided a spot urine sample for protein analysis (the recruitment sample) and
were asked to collect a 24-hour urine sample, which was stored for secondary analysis. A further spot
sample of urine was taken immediately before delivery.
Main outcome measures: Outcome data were collected from hospital records. There were four index
tests on a spot sample of urine: (1) SPCR test (conducted at the local laboratory); (2) SPCR test [conducted
at the central laboratory using the benzethonium chloride (BZC) assay]; (3) SPCR test [conducted at the
central laboratory using the pyrogallol red (PGR) assay]; and (4) SACR test (conducted at the central
laboratory using an automated chemistry analyser). The comparator tests on 24-hour urine collection were
DOI: 10.3310/hta21610 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 61
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Waugh et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
vii
a central test using the BZC assay and a central test using the PGR assay. The primary reference standard
was the NICE definition of severe PE. Secondary reference standards were a clinician diagnosis of severe PE,
which is defined as treatment with magnesium sulphate or with severe PE protocol; adverse perinatal
outcome; one or more of perinatal or infant mortality, bronchopulmonary dysplasia, necrotising enterocolitis
or grade III/IV intraventricular haemorrhage; and economic cost and outcomes. Health service data on
service use and costs followed published economic models.
Results: In total, 959 women were available for primary analysis and 417 of them had severe PE. The
diagnostic accuracy of the four assays on spot urine samples against the reference standards was similar.
The three SPCR tests had sensitivities in excess of 90% at prespecified thresholds, with poor specificities and
negative likelihood ratios of ≥ 0.1. The SACR test had a significantly higher sensitivity of 99% (confidence
interval 98% to 100%) and lower specificity. Receiver operating characteristic (ROC) curves were similar (area
under ROC curve between 0.87 and 0.89); the area under the central laboratory’s SACR curve was significantly
higher (p = 0.004). The central laboratory’s SACR test was the most cost-effective option, generating an
additional 0.03 quality-adjusted life-years at an additional cost of £45.07 compared with the local laboratory’s
SPCR test. The probabilistic analysis showed it to have a 100% probability of being cost-effective at the
standard willingness-to-pay threshold recommended by NICE.
Limitations: Implementation of NICE guidelines has led to an increased intervention rate in the study
population that affected recruitment rates and led to revised sample size calculations.
Conclusions: Evidence from this clinical study does not support the recommendation of 24-hour urine
sample collection in hypertensive pregnant women. The SACR test had better diagnostic performance
when predicting severe pre-eclampsia. All four tests could potentially be used as rule-out tests for the NICE
definition of severe PE.
Future work: Testing SACR at a threshold of 8 mg/mmol should be studied as a ‘rule-out’ test
of proteinuria.
Trial registration: Current Controlled Trials ISRCTN82607486.
Funding: This project was funded by the National Institute Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 21, No. 61.
See the NIHR Journals Library website for further project information.
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Plain English summary
P re-eclampsia (PE) occurs in pregnant women and stops after the baby is born. It starts in the placenta(which joins the mother and baby) and spreads, damaging blood vessels in the mother, and can
cause fits, organ failure and death. The baby’s growth can slow and stillbirth can occur. If the mother’s
kidneys are damaged, protein in the blood leaks through into the urine. This is proteinuria. Proteinuria and
raised blood pressure (BP) are usually early signs of PE and pregnant women then go to hospital for more
tests. Severe PE is a list of symptoms, signs and abnormal blood tests showing that PE is damaging the
liver, kidney and brain. It includes very high BP.
This study looked at two hospital tests used to measure proteinuria: the spot protein–creatinine ratio
(SPCR) test and the spot albumin–creatinine ratio (SACR) test. We wanted to know if these tests could
identify women who are less likely to have severe PE.
The women we tested already had high BP and at least some protein in their urine. We found that:
l 4 in 10 women got severe PE
l when SPCR and SACR tests were negative they identified women who were 10 times less likely to get
severe PE
l the tests did not show which babies would become ill
l doctors in the study put only one-third of women who got severe PE on a plan of special care.
These results could be used to help doctors decide which women with possible PE may not need so much
intensive care.
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Scientific summary
Background
Pre-eclampsia (PE) is a multisystem disorder of pregnancy associated with new raised blood pressure (BP) and
proteinuria. It remains the second leading cause of direct maternal deaths in the UK and causes 20% of all
stillbirths. The 2010 National Institute for Health and Care Excellence (NICE) guideline for the management
of hypertensive disorders of pregnancy differentiates PE from gestational hypertension by the presence
of new significant proteinuria. This differentiation is critical in terms of monitoring and management, cost
and outcomes. NICE has acknowledged the lack of evidence relating both to the diagnosis of significant
proteinuria in pregnant women and the prognostic value of various urinary protein thresholds. The aim of
the study was to evaluate the various methods of measuring proteinuria in pregnant women with suspected
PE both in the diagnosis of significant proteinuria and in the prediction of clinically significant outcomes and
cost-effectiveness.
Objectives
The primary objective of the study was to evaluate the accuracy of quantitative assessments of spot
protein–creatinine ratio (SPCR) and spot albumin–creatinine ratio (SACR) at different thresholds in
predicting severe PE compared with 24-hour urine protein measurement in pregnant women with
hypertension and suspected proteinuria.
The secondary objectives, after amendment, were to:
l investigate differences between laboratory assay methods for 24-hour proteinuria estimation
l evaluate the accuracy of quantitative assessments of SPCR and SACR at different thresholds in
predicting adverse perinatal outcomes
l estimate the diagnostic utility of SPCR or SACR tests as a potential replacement for 24-hour protein
estimation by developing a decision-analytic model
l assess the cost-effectiveness using incremental cost per quality-adjusted life-year (QALY) gained by the
mother and baby in each test compared with standard practice.
Methods
Study conduct
As part of routine antenatal care to assess for PE, pregnant women have their BP measured and a urine
sample checked for protein using a urine dipstick. Potential participants were identified from women with
suspected PE, who were subsequently referred to a hospital maternity assessment unit, delivery suite or
outpatient department for repeat assessments.
The inclusion criteria for the study were pregnant women aged ≥ 16 years, who were at > 20 weeks’
gestation with new hypertension (systolic BP of ≥ 140 mmHg and/or diastolic BP of ≥ 90 mmHg) and a
trace or more proteinuria on an automated dipstick urinalysis, and who were able to give written
informed consent.
Women with pre-existing renal disease (proteinuria before 20 weeks), pre-gestational diabetes or chronic
hypertension were excluded.
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All eligible women were given a patient information sheet and invited to participate by a research midwife.
Eligible women who consented to take part in the study had provided a routine spot urine sample for
protein analysis (the recruitment sample). This sample of urine was used to provide five 1-ml aliquots,
which were frozen and stored for secondary analysis. The remainder was sent to a local laboratory for
quantitative assessment of SPCR.
Participants were asked to collect urine for 24 hours in a collection container, as either an inpatient or an
outpatient depending on their clinical management plan. An aliquot of the 24-hour sample was frozen
and stored for secondary analysis.
A further spot sample of urine was taken and stored for analysis immediately before delivery.
Six weeks after giving birth, women were followed up and the pregnancy diagnosis was confirmed.
Outcome data were collected from hospital records.
Index tests
There were four index tests on a spot sample of urine: (1) SPCR test (conducted at the local laboratory),
(2) SPCR test [conducted at the central laboratory using the benzethonium chloride (BZC) assay],
(3) SPCR test [conducted at the central laboratory using the pyrogallol red (PGR) assay] and (4) SACR test
(conducted at the central laboratory using an automated chemistry analyser). The comparator tests on
24-hour urine collection were a central test using the BZC assay and a central test using the PGR assay.
Reference standards
The primary reference standard was the NICE definition of severe PE: PE with severe hypertension,
symptoms, biochemical and/or haematological impairment.
l PE is defined as new hypertension after 20 weeks’ gestation (systolic BP of ≥ 140 mmHg and/or
diastolic BP of ≥ 90 mmHg) and significant proteinuria (≥ 300 mg from 24-hour urine collection using
the central laboratory’s BZC assay).
l Severe hypertension is defined as systolic BP of ≥ 160 mmHg or diastolic BP of ≥ 110 mmHg.
l Severe features included at least one of severe headache, visual disturbances, problems with vision,
severe pain just below the ribs or vomiting, papilloedema, signs of clonus (three or more beats), liver
tenderness, HELLP (Haemolysis, Elevated Liver enzymes, Low Platelets) syndrome, platelet levels below
100 × 109/l, abnormal liver enzyme levels (alanine aminotransferase or aspartate aminotransferase levels
of > 70 U/l).
A second reference standard was a clinician diagnosis of severe PE, which was defined as those instances
in which a woman was treated with magnesium sulphate or put on a severe PE protocol. The use of such
a protocol is a core compliance standard for clinical risk assessment followed by all participating units.
Adverse perinatal outcome (composite identified by Delphi survey of clinicians) was defined as one or
more of perinatal or infant mortality, bronchopulmonary dysplasia, necrotising enterocolitis or grade III/IV
intraventricular haemorrhage. The definition used for bronchopulmonary dysplasia was oxygen dependence
at 36 weeks of postmenstrual age (gestational age at delivery plus chronological age of baby).
For the economic analysis, the diagnostic accuracy of each test, derived from the statistical analysis of the
clinical study, was combined with the intervention cost and length of stay in maternal and neonatal units
obtained from study sites and, cost and utility assumptions in the hypertension in pregnancy models
published in NICE clinical guideline (CG) number 107 (NICE. Hypertension in Pregnancy: The Management
of Hypertensive Disorders During Pregnancy. CG107. London: NICE; 2010). The study estimated the
incremental cost per QALY in deterministic and probabilistic sensitivity analyses.
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Analysis
Diagnostic performance of the index tests against the reference standards were compared using prespecified
thresholds of 30 mg/mmol for SPCR and 2 mg/mmol for SACR. Sensitivities, specificities, positive likelihood
ratios and negative likelihood ratios (LR–s) and area under receiver operating characteristic (ROC) curves were
calculated. For the economic evaluation, a modelling approach was used to estimate the incremental cost
per quality-adjusted life-year (QALY) gained of the test, comparing comparator and other index tests against
the local laboratory’s SPCR test (standard care comparator). The analysis was based on the clinician diagnosis
of severe PE as the reference standard.
A rule-out test for severe PE would require a LR– of ≤ 0.1 and a sensitivity of ≥ 90% with a high specificity.
Sample size
To demonstrate that a quantitative assessment of SPCR or SACR at a given cut-off point could rule out
severe PE, the original sample size required 240 women with severe PE. Assuming that 5% of recruited
women would develop severe PE, the recruitment target was set at 3000 women with new hypertension
and suspected proteinuria.
Interim reports indicated that the prevalence of severe PE might be higher; the Trial Steering Committee
recommended that the proportion of women with severe PE be estimated from the first 500 participants.
The laboratory assessments (NICE definition) were not available for all participants, so a surrogate
definition was agreed (the clinician diagnosis of severe PE). Using this, the prevalence was estimated to be
78 out of 500 (15.5%) and a new recruitment target was calculated of 1790 women.
Results
Population
In total, 1823 women were recruited and, of these, 959 had no missing test data for all four test index
assays and were available for primary analysis. There were 475 women with PE (NICE definition), of which
417 out of 475 (88%) had severe PE.
Using the NICE definition of severe PE, the prevalence in this group was 43% (417/959), the majority of
whom (339/417) had severe hypertension. In total, 23% of women delivered prior to 36 completed weeks
of gestation (preterm) and 6% of babies had severe perinatal morbidity. There were no maternal deaths in
this group, but there were still 30 cases of eclampsia.
Using the surrogate clinician diagnosis of severe PE, the prevalence rate was 20% (193/959) of women,
of whom the majority (149/193) both followed a severe PE protocol and received magnesium sulphate.
Only 32% of those with severe PE (NICE definition) had a clinician diagnosis of severe PE, and 8% of those
with a NICE definition of severe PE and 15% with a clinical definition had an adverse perinatal outcome.
Primary objective analysis
The diagnostic performance of the four assays testing the spot urine sample at recruitment against the
reference standard of severe PE (NICE definition) was similar. The three SPCR tests had sensitivities in
excess of 90% at prespecified thresholds, with poor specificities and LR–s of ≥ 0.1. The central laboratory’s
SACR test had a significantly higher sensitivity of 99% [95% confidence interval (CI) 98% to 100%] and
lower specificity. The ROC curves, when overlain, were similar (area under ROC curve between 0.87 and
0.89); the area under the central laboratory’s SACR curve was significantly greater than the local
laboratory’s SPCR curve (p = 0.004).
Using the severe PE (the clinician diagnosis) as reference standard, the three SPCR tests had sensitivities
below 90% at the prespecified thresholds. The central laboratory’s SACR test had significantly higher
sensitivity (97%, 95% CI 93% to 99%) than the local laboratory’s SPCR test, but with a significantly lower
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specificity (16%, 95% CI 14% to 19%). When overlain, the ROC curves for the assays were similar, and
demonstrated a much poorer diagnostic performance than with the NICE definition of severe PE. The
negative predictive values of each of the three SPCR tests was 92–93% (98% for the SACR test), so a
negative result from one of these tests brings the risk of developing severe PE down to 7–8% (2% for the
SACR test), compared with the pre-test risk of 43%.
Comparing the central laboratory’s PGR and BZC assay methods to diagnose significant proteinuria from
the 24-hour urine sample, 55% and 50%, respectively, of samples were identified as having significant
proteinuria (≥ 300 mg/24 hours). Consequently, the proportion of women categorised as having severe PE
(NICE definition) was greater using the PGR assay (48%) than using the BZC assay (43%). Using the data
from the PGR assay in the reference standard, the diagnostic performance of the index tests was similar:
the three SPCR assays had sensitivities above 90% with low specificities. LR–s were slightly higher than
those found using the BZC assay in the proteinuria component of the definition.
There is a non-linear relationship when comparing the two assays using a Bland–Altman plot. Up to values
of around 1200 mg/l the PGR assay value is typically higher, whereas from 1200 to 2000 mg/l the PGR
assay value is typically lower.
In terms of adverse perinatal outcomes, the diagnostic performance of the four assays testing the spot
urine sample at recruitment against the reference standard of adverse perinatal outcomes was similar. The
three SPCR tests had sensitivities below 80% at prespecified thresholds, with poor specificities. The central
laboratory’s SACR test had a significantly higher sensitivity of 94% (95% CI 84% to 98%) and lower
specificity of 14% (95% CI 12% to 16%), with poor likelihood ratios. The ROC curves, when overlain,
were similar, and all demonstrated poor diagnostic performance.
Economic evaluation
The standard care comparator (local SPCR test) generated 52.39 maternal and neonatal QALYs, at a
lifetime cost of £6621. Across the six tests, the differences in cost and QALYs were small; the incremental
cost-effectiveness analysis found that there was a difference of only 0.04 QALYs between the best and
worst performing test. Cost differences were greater, with urine dipstick testing alone generating £66
more than the local laboratory’s SPCR test. The central laboratory’s SACR test was the most effective
strategy (52.42 QALYs gained).
Conclusions
From the results of this study we can draw the following conclusions:
1. The SACR test has marginally better diagnostic performance characteristics than the SPCR test when
predicting severe PE according to the NICE CG107 definition.
2. All four tests could be used as rule-out tests for the NICE definition of severe PE, in that if we get a
negative test result the odds of severe PE are considerably reduced (by 10-fold or more) compared
with the odds in the target population as a whole before we do the test.
3. The collection of a 24-hour urine sample confers no additional value over a spot urine sample to
quantify proteinuria in women with hypertension in pregnancy.
4. The threshold level of SPCR that performs best for the prediction of severe PE is the current threshold
of 30 mg/mmol.
5. The threshold level of SACR that is equivalent to this in terms of clinical performance is 8 mg/mmol.
6. Urine dipstick testing without laboratory testing of SPCR or SACR performs poorly as a predictive
strategy for either severe PE or adverse perinatal outcome.
7. The measurement of ‘maximum proteinuria’ or a ‘rise in proteinuria’ confers no advantage in the
prediction of severe PE or adverse perinatal outcomes in hypertensive pregnancies.
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8. Biochemical assays for proteinuria are not universal and as such some assays (e.g. PGR assay) will
overdiagnose PE compared with the BZC assay by at least 5%.
9. The SACR test was deemed to have a 100% probability of being the most cost-effective option at the
standard willingness-to-pay threshold of £20,000–30,000 per QALY recommended by NICE.
10. Clinicians continue to plan care (and interpret results) in an inconsistent manner when caring for
women with severe PE.
11. The non-uniform application of NICE CG107 severe PE management algorithms and definitions by
clinicians does not confer any additional benefits in reducing the number of women who will have
adverse perinatal outcome.
Implications for clinical practice
l Evidence would suggest that all proteinuria assessments should be performed by an initial dipstick
screening test read on an automated dipstick reader, and for all non-negative tests a SACR test should
be considered. In the absence of a SACR test being available, a SPCR test could be used as an alternative.
l Given the intermethod/laboratory variability of protein assays demonstrated, all ‘protein’ tests should be
viewed with extreme caution and consideration should be given to a urine albumin assay being employed
for future definitions.
l Clinically significant proteinuria should remain defined at a level of 8 mg/mmol as measured by the
SACR test or 30 mg/mmol as measured by the SPCR test.
l The evidence from this clinical study does not support the recommendation of 24-hour urine sample
collection in hypertensive pregnant women.
l Once confirmed to be > 30 mg/mmol, no further proteinuria measurements are required during
hypertensive pregnancy.
l Whenever possible, proteinuria measurements should be by a single (accepted as standard) assay.
When this is not a BZC assay, clinicians should be aware that some assays can overdiagnose proteinuria
and, hence, PE.
l In the presence of hypertension in pregnancy without proteinuria, the progression to severe maternal
disease is unlikely (7% for SPCR and 2% for SACR). Adverse maternal and perinatal outcomes do
occur and all women with gestational hypertension should be closely monitored.
Trial registration
This trial is registered as ISRCTN82607486.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Clinical background
Pre-eclampsia (PE) is a multisystem disorder of pregnancy associated with raised blood pressure (BP) and
proteinuria.1 Hypertensive disorders in pregnancy (HDP) remain the second leading cause of direct maternal
deaths in the UK and account for 20% of all stillbirths.2,3 One in five women with hypertension is diagnosed
with PE, resulting in complex treatment and substantial health-care costs.1 Women with the severest forms
of PE require high-dependency care,1 although definitions of severe disease are not consistent. PE is also
responsible for significant infant morbidity related to fetal growth restriction and prematurity resulting in
prolonged neonatal intensive care treatment and lifelong handicaps; the additional NHS costs to care for a
preterm baby born before 33 and 28 weeks’ gestation are £61,509 and £94,190, respectively.1 Extra costs
of £939M for the care of preterm babies per year in the NHS are linked to neonatal care.1
Proteinuria measurement has been a key component of the screening and diagnostic strategies for modern
antenatal care. Normal ranges have been defined,4 but the optimal method of detection remains uncertain.5,6
Furthermore, the diagnosis of PE does not always imply that serious maternal or perinatal morbidity will
occur. None of the diagnostic features of PE is predictive of severe adverse outcome.7
The potential impact of early and accurate assessment of PE is enormous. The reliable diagnosis of significant
proteinuria is critical in women with hypertension in pregnancy because it distinguishes those with PE
from those with isolated hypertension; this distinction determines future monitoring and management.1
Furthermore, the determination of the most appropriate threshold for abnormal proteinuria that predicts
clinical outcome helps to better focus resource on high-risk women and reduce unnecessary intervention.
Currently, women with suspected PE undergo 24-hour proteinuria testing, mainly as inpatients, to evaluate
the severity of the condition. The cost associated with 24-hour protein measurement and additional testing
needs to be evaluated against identifying women with PE and avoiding the mortality, morbidity and costs
associated with undiagnosed PE.
The National Institute for Health and Care Excellence (NICE) acknowledges the paucity of evidence relating
to the diagnosis of significant proteinuria and the unclear prognostic value of various urinary protein
thresholds.1 They have highlighted the need for ‘large, high-quality prospective studies comparing the various
methods of measuring proteinuria (automated reagent-strip reading devices, urinary protein–creatinine ratio,
urinary albumin–creatinine ratio, and 24-hour urine collection) in women with new-onset hypertensive
disorders during pregnancy’.1
Our proposed study aims to address this shortfall in evidence by determining which method of measurement
is most accurate in predicting not only PE but, more importantly, clinically significant outcomes. This will help
to inform decisions regarding clinical management of gestational hypertensive disorders during pregnancy.
Description of technology
Comparative test
Measurement of 24-hour urine protein is currently the gold standard for the assessment of proteinuria in
pregnancy. However, this test is associated with significant costs related to hospital admission, as often
women are admitted as an inpatient for up to 48 hours until the results become available. Furthermore,
the measurement is subject to errors (in as many as 20% of patients) as a result of incomplete collection.
Diagnosis of proteinuria in HDP also varies with the type of laboratory assay used. These errors are
compounded for other point-of-care (POC) technologies.8
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1
Index tests
Proteinuria estimation by a urinary spot protein–creatinine ratio (SPCR) test or a urinary spot albumin–creatinine
ratio (SACR) test in women with suspected PE is available as a laboratory test performed on a random ‘spot’
sample of urine.
A reliable, accurate and cost-effective SPCR or SACR test, that is equivalent or better than 24-hour protein
estimation at predicting adverse maternal and fetal outcomes, could be employed as the primary test in
the assessment of women with suspected PE. Furthermore, given the rising costs of inpatient care, the use of
a SPCR test or a SACR test has the potential to deliver significant cost improvements. A clearer understanding
of the threshold of proteinuria (by any measurement) that predicts increased risks of adverse maternal and
fetal outcomes will allow the concentration of scarce NHS resource onto the more intensive monitoring of
fewer women.
Summary of current evidence
Current recommendations for assessment of proteinuria vary. Recently published NICE guidelines1 in the
UK suggest the use of an automated reagent strip reading device to detect proteinuria. In women with a
result of 1+ or more, the use of SPCR or 24-hour urine collection is recommended to quantify proteinuria.
Significant proteinuria is defined as a SPCR greater than 30mg/mmol or a validated 24-hour urine collection
of > 300 mg/24 hours. When 24-hour urine collection is used to quantify proteinuria, a recognised method of
evaluating completeness of the sample is recommended.1 The Society of Obstetricians and Gynaecologists
of Canada9 suggests using urinary dipstick testing to screen for proteinuria, with the definition of significant
proteinuria similar to the NICE guidelines. The American College of Obstetricians and Gynecologists10 consider
24-hour urine protein estimation of > 300 mg as significant proteinuria for a diagnosis of PE.
Work leading to the trial
Diagnostic accuracy of spot protein–creatinine ratio/spot albumin–creatinine ratio in
assessing proteinuria in women with hypertensive disorders in pregnancy
Price et al.,11 in 2005, and Cote et al.,12 in 2008, performed systematic reviews of 1214 women with
gestational hypertension. The SPCR test, with a cut-off point of 30 mg/mmol, had a pooled sensitivity of
83.6% [95% confidence interval (CI) 77.5% to 89.7%], a specificity of 76.3% (95% CI 72.6% to 80.0%),
a positive likelihood ratio (LR+) of 3.53 (95% CI 2.83 to 4.49) and a negative likelihood ratio (LR–) of 0.21
(95% CI 0.13 to 0.31). Both groups of authors concluded that the SPCR test was a reasonable ‘rule-out’
test for proteinuria of ≥ 300 mg/day in HDP. However, laboratory assays in the primary studies were not
well described. This led to the recommendation for future studies on using the SACR test to predict
significant proteinuria and clinical outcomes.
Evaluation of proteinuria thresholds and assays in predicting adverse clinical outcomes
The authors have assessed the use of different laboratory assays to measure 24-hour proteinuria in
pregnancy.13 The prevalence of proteinuria of > 300mg/24 hours and, hence, the prevalence of PE differed
between the two assays studied [24.9% for the Bradford assay and 70.1% for the benzethonium chloride
(BZC) assay]. The threshold of 300mg/24 hours performed poorly as a predictor of adverse outcomes.13 At the
threshold of 500 mg/24 hours, the BZC assay predicted severe hypertension with a LR+ of 1.51 (95% CI 0.99
to 2.28) and small for gestational age with a LR+ of 1.72 (95% CI 1.11 to 2.66). However, at the threshold
of 500 mg/24 hours, the LR+ for the Bradford assay for severe hypertension was 2.15 (95% CI 1.07 to 4.34),
for birthweight of less than the 10th centile was 2.79 (95% CI 1.40 to 5.54) and for biochemical disease was
2.47 (95% CI 1.22 to 5.01). These data support the recommendation from NICE1 for prospective studies to
explore the relationship between individual assays for proteinuria and clinical outcome.
INTRODUCTION
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Point-of-care measurement of proteinuria
The authors have also investigated POC testing for proteinuria and albuminuria in pregnancy and PE.14–16
The SACR dipstick test and the fully quantitative SACR test were compared with 24-hour proteinuria. The
SACR dipstick testing did not improve detection rates whether automated or visual. Fully quantitative
measurement of SACR was a better predictor than any dipstick technique (LR+ 14.60, 95% CI 6.74 to
31.80; LR– 0.069, 95% CI 0.030 to 0.160).16
In a systematic review of six studies of visual dipstick analysis, Waugh et al.17 reported a pooled LR+ of
3.48 (95% CI 1.66 to 7.27) and a pooled LR– of 0.60 (95% CI 0.45 to 0.80) for predicting proteinuria
at a level of 300 mg/24 hours at the 1+ or greater threshold. They concluded that the accuracy of dipstick
urinalysis with a 1+ threshold in the prediction of significant proteinuria is poor and, therefore, of limited
clinical value.
Our study comparing semiquantitative and fully quantitative POC tests for albuminuria and proteinuria found
automated dipstick urinalysis to have better predictive values for significant proteinuria (LR+ 4.27, 95% CI 2.78
to 6.56; LR– 0.225, 95% CI 0.14 to 0.37) compared with conventional visual dipstick urinalysis (LR+ 2.27,
95% CI 1.47 to 3.51; LR– 0.635, 95% CI 0.49 to 0.82). Dipstick microalbumin–creatinine ratio testing did not
improve overall detection rates with automated or visual testing. The fully quantitative POC test of SACR was
better than any dipstick technique (LR+ 14.6, 95% CI 6.74 to 31.8; LR– 0.069, 95% CI 0.030 to 0.16).16
These studies have informed the development of NICE clinical guideline (CG) number 107.1
Systematic review of tests that predict onset of pre-eclampsia
The authors have evaluated the accuracy of tests in predicting the onset of PE by a systematic review of
the literature.18 This study concluded that no current tests employed in screening for PE were sufficiently
accurate or effective to become part of routine care. One of the recommendations from that project was
to evaluate prognostic or predictive features, such as proteinuria, that are associated with maternal and
fetal complications once PE has started.
Systematic reviews on the accuracy of tests to predict complications in pre-eclampsia:
TIPPS study
We have conducted systematic literature reviews to assess the predictive value of five of the commonly
performed tests in PE. We analysed more than 25,000 citations and reviewed 60 relevant studies.
Although we conducted good-quality reviews, including one on proteinuria, it was hard to provide
recommendations on the value of tests because of the deficiencies in the primary studies. However,
the data collated give face validity of the choice of tests that have been chosen for use in the study.19
Development and validation of the PREP study
We have recently been funded by the Health Technology Assessment (HTA) programme to undertake
the first prognostic study to develop a prediction rule for adverse outcomes in early-onset PE that will
provide personalised estimates of maternal and fetal risks. The Prediction model for Risk of complications
in Early-onset Pre-eclampsia (PREP) study will achieve this by validating the model in two prospective
external data sets in the Netherlands and Canada. The data from the PREP study will complement the
current project in evaluating the association between proteinuria and adverse outcomes. Furthermore,
the study will also provide valuable data on outcomes of women with severe PE to further populate the
decision-analytic model for an economic evaluation.
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Chapter 2 Methods and design
Aims and objectives
The aim of this study was to evaluate the measurement of proteinuria in women with suspected PE.
This includes women with new hypertension of ≥ 140/90 mmHg and a trace or greater of proteinuria
using an automated dipstick analysis. By determining the most appropriate method and threshold for
measuring proteinuria that predicts PE and its severity, it may be possible to reduce unnecessary
intervention in women without PE.
Primary objective
To evaluate the accuracy of quantitative assessments of SPCR and SACR at different thresholds in
predicting severe PE compared with a 24-hour urine protein measurement in pregnant women with
hypertension and suspected proteinuria.
Secondary objectives
The secondary objectives of this study were to:
l assess the accuracy of POC assessments of SPCR and SACR at different thresholds in diagnosing PE
compared with a 24-hour urine protein measurement
l identify the laboratory assay method of 24-hour proteinuria that is most accurate in the assessment
of PE
l estimate the accuracy of quantitative assessments of SPCR and SACR at different thresholds in
predicting adverse fetal outcomes
l estimate the diagnostic utility of a SPCR test or a SACR test as a potential replacement for 24-hour
protein estimation by developing a decision-analytic model
l assess the cost-effectiveness using incremental cost per quality-adjusted life-year (QALY) gained by the
mother and baby in each test compared with standard practice.
For the statistical analysis plan, these have been amended to:
l evaluate the accuracy of POC assessments of SPCR and SACR at different thresholds in predicting
severe PE compared with a 24-hour urine protein measurement
l investigate differences between laboratory assay methods for 24-hour proteinuria
l evaluate the accuracy of both quantitative and POC assessments of SPCR and SACR at different
thresholds in predicting adverse perinatal outcomes.
Study design
This was a prospective cohort study to evaluate diagnostic accuracy, which also undertook a decision-analytic
modelling and cost-effectiveness analysis. The study was open to recruitment for a total of 33 months.
Research Ethics Service Committee A favourable opinion from the Research Ethics Committee was sought
and granted for the original study (reference number 12/NE/0301) from the National Research Ethics Service
Committee North East – County Durham & Tees Valley. This became the National Research Ethics Service
Committee North East – Newcastle and North Tyneside 2 for subsequent amendments.
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Setting
The study was conducted in a total of 36 obstetric units in England. The last day of study recruitment was
on 30 November 2015. Data were collected prospectively; participants were sampled consecutively until
the target sample size was reached.
Inclusion criteria
Pregnant women aged ≥ 16 years who were at > 20 weeks’ gestation with confirmed gestational
hypertension (systolic BP of ≥ 140 mmHg and/or diastolic BP of ≥ 90 mmHg) and trace or greater of
proteinuria on an automated dipstick urinalysis, who are able to given written informed consent.
Exclusion criteria
Women aged < 16 years or women with new hypertension but no proteinuria on automated dipstick
urinalysis, proteinuria before 20 weeks’ gestation, pre-existing renal disease, pre-gestational diabetes and
chronic hypertension. Women who were unable to provide written informed consent could not take part.
Identification and screening
Potential participants were identified from women during admission to the hospital in the maternity
assessment unit, delivery suite or outpatient department, subject to meeting the study inclusion and
exclusion criteria.
All eligible women were given a patient information sheet at their time of booking for antenatal care to
read and consider. The information sheets were made available in Urdu and Polish, as these were two of
the most commonly spoken languages in the participating sites.
During pregnancy, as part of routine care, women have their BP monitored and midwives checked protein
in collected urine samples using a urine dipstick. Women with high BP and trace proteinuria (who had
suspected PE) were referred to a day assessment unit for regular check-ups. During a regular check-up,
BP was measured and urine protein was assessed from another urine sample (POC sample) using a dipstick
and an automated urinalysis machine. Women with confirmed hypertension and a trace or more of protein
in this sample were eligible for the study and invited to participate by a research midwife.
Recruitment and consent
All women had the opportunity to ask questions about the study. Study discussions were undertaken by
the research midwives or research nurses as per the site delegation log. If willing, written informed consent
was obtained from the woman by a delegation member of the study team. The original signed consent
form was held in the investigator site file, with a copy of it placed in the medical notes and a copy given to
the participant.
It was clearly stated that the woman had the right to withdraw her participation at any point in the study
without having to give a reason.
Reference standards and other outcomes
Severe pre-eclampsia (National Institute for Health and Care Excellence definition)
Following the 2010 NICE definition,1 severe PE was defined as either (1) severe hypertension (systolic BP of
≥ 160 mmHg or diastolic BP of ≥ 110 mmHg) and proteinuria (see Proteinuria), or (2) mild or moderate
hypertension (systolic BP of ≥ 140 mmHg and/or diastolic BP of ≥ 90 mmHg) and proteinuria with one or
more of the following: severe headache, visual disturbances, problems with vision, severe pain just below
the ribs or vomiting, papilloedema, signs of clonus (three or more beats), liver tenderness, HELLP
(Haemolysis, Elevated Liver enzymes, Low Platelets) syndrome, platelet levels below 100 × 109/l or abnormal
liver enzyme levels [alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels of > 70 U/l].
METHODS AND DESIGN
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Proteinuria
Proteinuria was defined as ≥ 300 mg of protein from a 24-hour urine collection using the central
laboratory’s (Kent) BZC assay.
Severe pre-eclampsia (clinician diagnosis)
A clinician diagnosis of severe PE was defined as when a woman was treated with magnesium sulphate or
put on a severe PE protocol.
Adverse perinatal outcome
A composite adverse perinatal outcome was identified by a Delphi survey of clinicians. This comprises one or
more of the following: perinatal or infant mortality, bronchopulmonary dysplasia, necrotising enterocolitis or
grade III or IV intraventricular haemorrhage. The definition used for bronchopulmonary dysplasia was oxygen
dependence at 36 weeks’ postmenstrual age (gestational age at delivery plus chronological age of baby).
Sample size
The sample size for the study was chosen to allow for a demonstration that a quantitative assessment of
SPCR or SACR at a given cut-off point could safely rule out the possibility of severe PE. In diagnostic
testing terms, this means a test with a LR– of ≤ 0.1 and a sensitivity of at least 90% with high specificity.
Previous studies have suggested that SPCR or SACR testing (when fully quantitative) may achieve this.16
To demonstrate with 80% power that sensitivity is at least 90% within 95% confidence limits, assuming
that sensitivity is actually 95%, requires 240 women with severe PE, as determined using the power one
proportion command in Stata version 13 (Stata Corporation, College Station, TX, USA). The original sample
size calculation assumed that 5% of recruited women would develop severe PE, with a negligible number
of missing outcome data, and the recruitment target was, therefore, set at 3000 women with new
hypertension and suspected PE.
Following indications in interim reports that the prevalence of PE may be higher than expected, the Trial
Steering Committee recommended that the proportion of women with severe PE should be estimated from
the first 500 participants to be recruited and that the target sample size should be re-estimated on this
basis. Because the laboratory assessments needed to determine severe PE, as defined in the protocol, were
not available for all participants (namely liver function results and platelet counts), it was necessary to use a
surrogate definition of PE that was agreed with the Trial Steering Committee. In total, 419 participants out
of the first 500 women had sufficient data to determine this surrogate outcome, and prevalence was
estimated to be 78 out of 500 (15.6%). With the additional assumption that 14% of participants would
have missing data on the primary outcome in the final analysis (also based on an interim analysis), the
recruitment target was revised to 1790 women with new hypertension and suspected PE.
Data collection
Urine samples
A small amount of urine (five 1-ml aliquots) was taken from each participant’s POC sample, frozen and
stored at –80 °C for secondary analysis. The remainder of the POC sample was sent to the local laboratory
to obtain quantitative assessments of SPCR.
Participants were then asked to collect urine for 24 hours in a collection container provided by the research
midwife. The research midwife gave detailed instructions on when the collection should start and finish.
The start of 24-hour urine collection could be up to 24 hours after the POC test. When a woman returned
her 24-hour urine sample, a small amount (five 1-ml aliquots) was frozen and stored at –80 °C. If clinically
indicated from the initial recruitment urine sample, the remainder of the 24-hour urine sample was sent to
the local biochemical laboratory to determine the 24-hour measurement of proteinuria.
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Participants were asked for a third, and final, urine sample immediately before delivery and, again,
five 1-ml aliquots were stored at –80 °C (delivery urine).
The aliquots of urine were sent from each of the participating sites to a central laboratory, East Kent Hospitals
Trust, for analysis using standardised methods. All data were entered into a clinical data management
software package supplied by MedSciNet (Stockholm, Sweden) that was configured to allow web-based entry
from each of the 36 clinical sites as well as the Kent laboratory.
Clinical information and POC test results were not available to the central laboratory that conducted
assessments of 24-hour proteinuria.
Medical notes
Demographic characteristics, medical history and other characteristics measured at baseline (including
referral to the day assessment unit) were obtained from participants’ medical notes.
Information, other than proteinuria, that was needed to determine a diagnosis of severe PE was obtained
from participants’ medical notes.
Information to determine adverse perinatal outcome was collected at birth and discharge from hospital
from the hospital case notes. Neonatal outcome data for the small number of babies admitted to the
neonatal unit were obtained by the midwives employed in each unit. When a mother or baby was
transferred to another neonatal unit, data were collected (when possible) from all the hospitals that
provided their care.
Primary analysis
Using quantitative assessments of SPCR and SACR as index tests and the NICE definition of severe PE as
the reference standard, non-parametric receiver operating characteristic (ROC) curves were plotted,
showing diagnostic performance at different cut-off points.20
This primary analysis used the central laboratory’s (Kent) BZC total protein assay from the 24-hour urine
sample to determine PE, and was conducted for each of the following assays using the spot urine sample
at recruitment:
1. a SPCR test from a local laboratory
2. a SPCR test using the BZC assay at a central laboratory (Kent)
3. a SPCR test using the pyrogallol red (PGR) assay at a central laboratory (Kent)
4. a SACR test from a central laboratory (Kent).
Diagnostic accuracy was summarised using the area under the ROC curve, as well as sensitivity, specificity,
positive predictive value, negative predictive value, and LR+ and LR– at prespecified cut-off points
(30 mg/mmol for SPCR12 and 2 mg/mmol for SACR).16
Areas under the ROC curves for the quantitative SPCR and SACR assays were compared using the
non-parametric method of DeLong et al.21 to give a CI and significance test for the difference in area,
with SPCR testing from a local laboratory as the comparator. Sensitivity and specificity at the prespecified
cut-off points were compared using McNemar tests for paired proportions.
These analyses were restricted to the subsample for which the 24-hour urine sample result and the four
assays were all non-missing.
METHODS AND DESIGN
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Secondary analyses
Point-of-care dipstick test
The POC test using the urine dipstick proteinuria result at recruitment was analysed to determine its
diagnostic performance, using the same methods and reference standard as the primary analysis (restricted
to the subsample for which the 24-hour urine sample result and dipstick test result were both non-missing),
and using the standard threshold of 1+.16
Proteinuria as reference standard
The primary analysis was repeated using proteinuria [≥ 300 mg/24 hours using the central laboratory’s
(Kent) BZC assay] as the reference standard in place of severe PE (NICE definition).1
Severe pre-eclampsia (clinician diagnosis) as reference standard
The primary analysis was repeated using clinician diagnosis of severe PE [magnesium sulphate or severe
pre-eclamptic toxaemia (PET) protocol] as the reference standard in place of the NICE definition. The
central laboratory’s BZC and PGR assays using the 24-hour urine sample were also included as index tests
in this analysis, as they were not part of the definition of the reference standard.
The two definitions of severe PE (clinician diagnosis and NICE definition) were cross-tabulated.
Prediction of adverse perinatal outcome
The four assays of the urine sample at recruitment and two assays of the 24-hour urine sample were
analysed to see how well they predicted adverse perinatal outcomes, using the same methods as the
primary analysis.
Receiver operating characteristic curves were plotted separately for the following as predictors of adverse
perinatal outcomes:
(a) change in SPCR from recruitment to delivery spot urine samples assessed using the BZC assay at the
central laboratory (Kent)
(b) maximum SPCR from recruitment and delivery spot urine samples assessed using the BZC assay at the
central laboratory (Kent).
These ROC curves were compared with the ROC curve for the central laboratory’s BZC assay of the
recruitment sample.
No cut-off points were specified a priori for the last two, and these analyses were considered exploratory.
Subgroup analysis
The primary analysis was repeated on the subgroup of women with 1+ or higher on the POC dipstick test,
that is excluding those with a ‘trace’ result only. This is the population of women who would currently be
referred for further testing.
Laboratory assay method for 24-hour proteinuria
The primary analysis was repeated using the central laboratory’s (Kent) PGR assay instead of the assay in
the NICE definition of severe PE.
The two definitions of severe PE (using the BZC and PGR assays) were cross-tabulated. Exploratory
investigation of the agreement between the central laboratory’s (Kent) BZC and PGR assays of total protein
from the 24-hour urine sample was undertaken using a Bland–Altman plot.22
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Changes to the protocol
Owing to the availability of POC testing in the UK and the availability and cost of the equipment needed,
the SPCR and fully quantitative SACR POC tests that were stated in the original study protocol were not
undertaken. This change was covered in substantial amendment 2 , which was added in version 2.0 of the
protocol, dated 7 April 2015. It is hoped that this can be completed as a separate piece of work in the future.
METHODS AND DESIGN
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Chapter 3 Results
For the DAPPA (spot protein–creatinine ratio and spot albumin–creatinine ratio in the assessment ofpre-eclampsia: a diagnostic accuracy study with decision-analytic model-based economic evaluation and
acceptability analysis) trial timeline and key milestones see Appendix 1.
Participant flow
The number of eligible participants consented and recruited was 1823. In total, 165 women had to be
withdrawn because they withdrew consent, refused or were unable to collect any samples after
recruitment, or the samples were collected but not frozen.
There were 1658 women who had completed patient records for inclusion in the final database. However,
the central laboratory’s test results for urinary protein in the 24-hour urine sample were not available for
212 women, leaving 1446 women for whom the primary outcome of severe PE could be determined
(Figure 1). The prevalence of severe PE in these women was 44% (638/1446). Note that even assuming
that none of the 212 women with missing test results developed severe PE, the prevalence of severe PE in
the 1658 eligible and consented women would still have been 38% (638/1658).
Unfortunately, local laboratory SPCR testing of the recruitment urine sample was not available for 476
women, and a further 10 women had missing central laboratory SPCR test data for the recruitment urine
sample (see Figure 1). To compare the diagnostic accuracy of the four assays (three central laboratory and
one local laboratory) on the recruitment urine sample, the analysis was restricted to those women with
data for all four assays, and excluded one other woman with missing adverse perinatal outcome (n = 959).
The prevalence of severe PE in this subsample was 43% (417/959), similar to the prevalence in the 1446
women with 24-hour urine protein sample data.
Characteristics of participants
The number of women by centre is shown in Table 1, for eligible and consented women, for women for
whom a diagnosis of severe PE using the NICE definition could be determined, and for women included in
the primary analysis. Baseline characteristics, including demographics, concurrent medication, medical
history and family history, are summarised in Table 2. BP at recruitment and spot urine protein, creatinine
and SPCR at recruitment are summarised in Table 3.
Reference standards and other outcomes
Reference standards and perinatal outcomes are summarised in Table 4 for women included in the
primary analysis.
Only 32% (134/417) of the women who met the NICE definition of severe PE had a clinician diagnosis of
severe PE, and, in addition, 11% (59/542) of women who did not meet the NICE definition had a clinician
diagnosis (Table 5).
The majority (149/193, 77%) of those with a clinician diagnosis of severe PE had both magnesium
sulphate treatment and followed a severe PE protocol (Table 6).
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Eligible and consented womena
(n = 1823)
With 24-hour sample at central laboratory
(n = 1446)
• No sample collected, n = 173
• Problem labelling samples, n = 29
• Samples destroyed as not frozen properly, n = 10
• No local SPCR of recruitment urine sample, n = 476
• No central laboratory SPCR of recruitment sample, n = 10
No data to determine adverse perinatal outcome 
(n = 1)
Available for analysis
(n = 959)
With proteinureab
(n = 475)
No proteinurea
(n = 484)
Severe
hypertensionc
(n = 339)
Moderate/mild
hypertensionc
(n = 136)
Symptomsd
(n = 78)
No symptoms
(n = 58)
With severe pre-eclampsia
(NICE definition)e
(n = 417)
Without severe pre-eclampsia
(NICE definition)
(n = 542)
Consent withdrawn for 165 women 
(n = 1658)
No 24-hour urine sample at central laboratory 
(n = 212)
Missing an index test for the primary analysis 
(n = 486)
FIGURE 1 Participant flow chart showing the number of eligible and consented women, the number for whom
a diagnosis of severe PE using the NICE definition could be determined, the number included in the primary
analysis and the number with severe PE. a, > 20 weeks’ gestation with confirmed gestational hypertension
(systolic BP of ≥ 140mmHg or diastolic BP of ≥ 90mmHg) and trace or more proteinuria on automated dipstick
analysis; b, 24-hour urine sample (the central laboratory’s BZC assay) total protein concentration of ≥ 300mg;
c, severe – systolic BP of ≥ 160mmHg or diastolic BP of ≥ 110mmHg, mild/moderate – systolic BP of ≥ 160mmHg
or diastolic BP of ≥ 110mmHg; d, severe headache, visual disturbances, problems with vision, severe pain just
below the ribs or vomiting, papilloedema, signs of clonus (three or more beats), liver tenderness, HELLP syndrome,
platelet levels below 100 × 109/l, abnormal liver enzyme levels (ALT or AST level of > 70 U/l); e, either (1) severe
hypertension and proteinuria or (2) mild/moderate hypertension and proteinuria with one or more symptoms.
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TABLE 1 Number of women by centre
Centre Trust
Number (%) of women
Eligible and
consented
(N= 1658)
Diagnosis of
severe PE could
be determined
(N= 1446)
Included in the
primary analysis
(N= 959)
Royal Victoria Infirmary The Newcastle upon Tyne
Hospitals NHS Foundation Trust
218 (13) 175 (12) 170 (18)
Whipps Cross, Newham and
The Royal London
Barts Health NHS Trust 131 (8) 116 (8) 103 (11)
St Thomas’ Hospital Guy’s and St Thomas’ NHS
Foundation Trust
128 (8) 120 (8) 84 (9)
James Cook University Hospital South Tees Hospitals NHS
Foundation Trust
87 (5) 70 (5) 42 (4)
North Tyneside General Hospital Northumbria Healthcare NHS
Foundation Trust
86 (5) 61 (4) 42 (4)
Sunderland Royal Hospital City Hosptials Sunderland NHS
Foundation Trust
77 (5) 72 (5) 67 (7)
John Radcliffe Hospital Oxford University Hospitals
NHS Foundation Trust
61 (4) 60 (4) 1 (< 1)
Warrington Hospital Warrington and Halton
Hospital NHS Foundation Trust
61 (4) 51 (4) 23 (2)
Royal Shrewsbury Hospital Shrewsbury and Telford
Hospital NHS Trust
58 (4) 58 (4) 28 (3)
St George’s Hospital St George's University Hospital
NHS Foundation Trust
50 (3) 42 (3) 26 (3)
Queen’s Hospital Burton Hospitals NHS
Foundation Trust
49 (3) 49 (3) 25 (3)
Milton Keynes Hospital Milton Keynes University
Hospital NHS Foundation Trust
45 (3) 40 (3) 27 (3)
Royal Cornwall Hospital Royal Cornwall Hospital
NHS Trust
44 (3) 42 (3) 36 (4)
St James’s University Hospital The Leeds Teaching Hospitals
NHS Trust
41 (2) 41 (3) 21 (2)
Queen Alexandra Hospital Portsmouth Hospitals
NHS Trust
41 (2) 29 (2) 26 (3)
Queen Elizabeth Hospital Gateshead Health NHS
Foundation Trust
37 (2) 28 (2) 20 (2)
Leicester Royal Infirmary University Hospitals of Leicester
NHS Trust
35 (2) 23 (2) 22 (2)
St Mary’s Hospital Central Manchester University
Hospitals NHS Foundation Trust
32 (2) 32 (2) 32 (3)
Southport and Ormskirk
Hospital
Southport and Ormskirk
Hospital NHS Trust
31 (2) 30 (2) 27 (3)
University Hospital of North Tees North Tees and Hospital NHS
Foundation Trust
30 (2) 30 (2) 15 (2)
Queen's Medical Centre Nottingham University
Hospitals NHS Trust
28 (2) 26 (2) 10 (1)
St Michael’s Hospital University Hospital Bristol NHS
Foundation Trust
27 (2) 24 (2) 21 (2)
North Manchester Hospital The Pennine Acute Hospitals
NHS Trust
27 (2) 24 (2) 0 (0)
continued
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TABLE 1 Number of women by centre (continued )
Centre Trust
Number (%) of women
Eligible and
consented
(N= 1658)
Diagnosis of
severe PE could
be determined
(N= 1446)
Included in the
primary analysis
(N= 959)
Royal Derby Hospital Derby Teaching Hospitals NHS
Foundation Trust
25 (2) 24 (2) 15 (2)
Norfolk and Norwich
University Hospital
Norfolk and Norwich University
Hospitals NHS Foundation Trust
25 (2) 20 (1) 3 (< 1)
Queen Charlotte and Chelsea
Hospital
Imperial College Healthcare
NHS Trust
24 (1) 17 (1) 12 (1)
South Tyneside District Hospital South Tyneside NHS
Foundation Trust
23 (1) 20 (1) 9 (1)
Royal Blackburn Hospital and
Burnley General Hospital
East Lancashire Hospitals
NHS Trust
21 (1) 16 (1) 11 (1)
Colchester General Hospital Colchester Hospital University
NHS Foundation Trust
19 (1) 18 (1) 16 (2)
Derriford Hospital Plymouth Hospitals NHS Trust 18 (1) 17 (1) 0 (0)
Arrow Park Hospital Wirral University Teaching
Hospital NHS Foundation Trust
15 (1) 12 (1) 8 (1)
Nottingham City Hospital Nottingham University Hospitals
NHS Trust
14 (1) 13 (1) 1 (< 1)
Worcestershire Royal Hospital Worcestershire Acute Hospitals
NHS Trust
13 (1) 10 (1) 9 (1)
Cumberland Infirmary North Cumbria University
Hospitals NHS Trust
12 (1) 12 (1) 0 (0)
University Hospital of North
Durham
County Durham & Darlington
NHS Foundation Trust
11 (1) 11 (1) 5 (1)
Stafford Hospital University Hospitals of North
Midlands NHS Trust (previously
Mid Staffordshire)
8 (< 1) 8 (1) 2 (< 1)
Peterborough City Hospital North West Anglia NHS
Foundation Trust
6 (< 1) 5 (< 1) 0 (0)
TABLE 2 Baseline characteristics
Demographic criteria
Eligible, consented
(not withdrawn)
(N= 1658)
Diagnosis of severe PE
(NICE definition) could
be determined (N= 1446)
Included in primary
analysis (N= 959)
Age (years)
Median (quartiles) 30 (25, 34) 30 (25, 34) 30 (26, 34)
Weight (kg)
Median (quartiles) 76 (65, 91) 76 (65, 91) 76 (64, 90)
Height (cm)
Median (quartiles) 164 (160, 168) 164 (160, 168) 164 (160, 168)
Body mass index (kg/m2)
Median (quartiles) 28 (24, 34) 28 (24, 34) 28 (24, 33)
Country of origin, n (%)
UK 1219 (74) 1059 (73) 706 (74)
Africa 93 (6) 88 (6) 59 (6)
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TABLE 2 Baseline characteristics (continued )
Demographic criteria
Eligible, consented
(not withdrawn)
(N= 1658)
Diagnosis of severe PE
(NICE definition) could
be determined (N= 1446)
Included in primary
analysis (N= 959)
Eastern European 82 (5) 71 (5) 38 (4)
Other 59 (4) 52 (4) 31 (3)
Western European 44 (3) 36 (2) 19 (2)
Pakistan 37 (2) 34 (2) 29 (3)
India 36 (2) 31 (2) 22 (2)
Bangladesh 32 (2) 28 (2) 20 (2)
Caribbean 28 (2) 22 (2) 17 (2)
South East Asia 14 (1) 11 (1) 8 (1)
Middle East 8 (< 1) 8 (1) 6 (1)
China 6 (< 1) 6 (< 1) 4 (< 1)
Family history, n (%)
PE 266 (16) 237 (16) 166 (17)
Hypertension/cardiovascular disease 692 (42) 609 (42) 408 (43)
Diabetes mellitus 569 (34) 500 (35) 328 (34)
Renal disease 37 (2) 32 (2) 24 (2)
Taking aspirin 373 (22) 336 (23) 213 (22)
Number of previous pregnancies beyond 20 weeks’ gestation, n (%)
0 1066 (64) 937 (65) 616 (64)
1 344 (21) 300 (21) 203 (21)
2 151 (9) 131 (9) 85 (9)
3 48 (3) 38 (3) 29 (3)
4 29 (2) 26 (2) 19 (2)
5 10 (1) 8 (1) 4 (< 1)
≥ 6 10 (1) 6 (< 1) 3 (< 1)
Number of previous pregnancies of 20 weeks’ gestation or less (including terminations), n (%)
0 1163 (70) 1002 (69) 664 (69)
1 337 (20) 308 (21) 209 (22)
2 85 (5) 71 (5) 45 (5)
3 43 (3) 38 (3) 24 (2)
4 16 (1) 13 (1) 5 (1)
≥ 5 14 (1) 14 (1) 12 (1)
Previous hypertension in pregnancy 298 (18) 264 (18) 183 (19)
Symptoms at recruitment, n (%)
Headache 666 (40) 572 (40) 381 (40)
Nausea 222 (13) 189 (13) 137 (14)
Vomiting 81 (5) 71 (5) 53 (6)
Epigastric pain 176 (11) 148 (10) 97 (10)
Visual disturbance 294 (18) 251 (17) 175 (18)
Reduced fetal movements 123 (7) 106 (7) 74 (8)
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TABLE 3 Blood pressure and spot urine at recruitment
Measurement
Median (quartiles)
Eligible and
consented
(n= 1658)
Diagnosis of severe PE
could be determined
(n= 1446)
Included in primary
analysis (n= 959)
Systolic BP (mmHg) 145 (140, 152) 145 (140, 152) 145 (140, 152)
Diastolic BP (mmHg) 94 (90, 99) 94 (90, 99) 94 (90, 100)
Urine protein concentration (mg/l)a 510 (250, 1420) 520 (250, 1405) 520 (250, 1360)
Urine creatinine concentration (mmol/l)a 12 (7, 18) 12 (7, 18) 12 (7, 18)
Urine protein–creatinine ratio (mg/mmol)a 46 (22, 132) 46 (22, 131) 46 (22, 129)
a Spot urine at recruitment, local data.
TABLE 4 Reference standards and perinatal outcomes for women included in the primary analysis
Standard and outcome Number of women (%) (n= 959)
Severe PE (the NICE definition) 417 (43)
Proteinuria 475 (50)
Severe PE (the clinician diagnosis) 193 (20)
Eclampsia 30 (3)
Gestational age < 36 weeks 223 (23)
Median (weeks) 37
Interquartile range (weeks) 36–39
Range (weeks) 23–43
Multiple birthsa 53 (6)
Adverse perinatal outcome 62 (6)
Perinatal/neonatal mortality 18 (2)
Bronchopulmonary dysplasia 27 (3)
Necrotising enterocolitis 7 (1)
Intraventricular haemorrhage 16 (2)
a One woman had triplets; the rest had twins.
TABLE 5 Comparison of NICE definition of severe PE with clinician diagnosis of severe PE for women in
primary analysis
Clinical diagnoses, number of women
NICE definition, number of women
Without severe PE With severe PE Total
Without severe PEa 483 283 766
With severe PEa 59 134 193
Total 542 417 959
a Severe PET protocol and/or magnesium sulphate treatment given.
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Of the 417 women with severe PE according to the NICE definition, 8% had an adverse perinatal outcome
compared with 5% of women without severe PE (p = 0.033) (Table 7). Of the 193 women with a clinician
diagnosis of severe PE, 15% had an adverse perinatal outcome, compared with 4% of women without a
clinician diagnosis of severe PE (p < 0.001) (Table 8).
Table 9 shows the prevalence of severe PE (according to both definitions) and adverse perinatal outcomes
separately for women aged < 35 years and for women aged ≥ 35 years, and also separately for women
aged < 40 years and for women aged ≥ 40 years.
TABLE 6 Magnesium sulphate treatment and severe PET protocol for women in primary analysis
PET protocol, number of women
Treatment, number of women
Without magnesium sulphate With magnesium sulphate Total
Without severe 766 13 779
With severe 31 149 180
Total 797 162 959
TABLE 7 Cross-tabulation of severe PE (NICE definition) against adverse perinatal outcome
NICE definition, number of women
Perinatal outcome, number of women
Without adverse With adverse Total
Without severe PE 515 27 542
With severe PE 382 35 417
Total 897 62 959
TABLE 8 Clinician diagnosis of severe PE vs. adverse perinatal outcome
Clinician diagnosed, number of women
Perinatal outcome, number of women
Without adverse With adverse Total
Without severe PEa 732 34 766
With severe PEa 165 28 193
Total 897 62 959
a Severe PET protocol and/or magnesium sulphate treatment given.
TABLE 9 Severe PE and adverse perinatal outcomes in different age groups
Women affected by
Age (years), n (%)
< 35 (N= 729) ≥ 35 (N= 230) < 40 (N= 907) ≥ 40 (N= 52)
Severe PE (NICE definition) 329 (45) 88 (38) 399 (44) 18 (35)
Severe PE (clinician diagnosis) 147 (20) 46 (20) 186 (21) 7 (13)
Adverse perinatal outcome 51 (7) 11 (5) 62 (7) 0 (0)
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Primary analysis
The diagnostic accuracy of the four assays using the spot urine sample at recruitment was compared using
prespecified thresholds of 30 mg/mmol for SPCR and 2 mg/mmol for SACR. Tables 10–13 show index test
results cross-tabulated against the reference standard (severe PE, NICE definition). Sensitivities, specificities, LR+s
and LR–s are shown in Table 14. The three SPCR tests all had sensitivity in excess of 90% at the prespecified
thresholds but with poor specificity. The central laboratory’s SACR test had significantly higher sensitivity (99%,
95% CI 98% to 100%) than the local laboratory’s SPCR test, but its specificity (23%, 95% CI 20% to 27%)
was significantly lower. The high sensitivities and LR–s of ≤ 0.1 suggest that all of the tests could be used as
TABLE 10 Cross-tabulation of the local laboratory’s SPCR testing of the recruitment urine sample (threshold
30mg/mmol) against severe PE (NICE definition)
Threshold (mg/mmol)
Number of women
Without severe PE With severe PE Total
< 30 309 27 336
≥ 30 233 390 623
Total 542 417 959
TABLE 11 Cross-tabulation of the central laboratory’s (Kent) SPCR testing of the recruitment urine sample using
the BZC assay (threshold 30mg/mmol) against severe PE (NICE definition)
Threshold (mg/mmol)
Number of women
Without severe PE With severe PE Total
< 30 333 29 362
≥ 30 209 388 597
Total 542 417 959
TABLE 12 Cross-tabulation of the central laboratory’s (Kent) SPCR testing of the recruitment urine sample using
the PGR assay (threshold 30mg/mmol) against severe PE (NICE definition)
Threshold (mg/mmol)
Number of women
Without severe PE With severe PE Total
< 30 302 22 324
≥ 30 240 395 635
Total 542 417 959
TABLE 13 Cross-tabulation of the central laboratory’s (Kent) SACR testing of the recruitment urine sample
(threshold 2mg/mmol) against severe PE (NICE definition)
Threshold (mg/mmol)
Number of women
Without severe PE With severe PE Total
< 2 126 3 129
≥ 2 416 414 830
Total 542 417 959
RESULTS
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TABLE 14 Diagnostic accuracy of the four assays of the recruitment urine sample, and the POC proteinuria dipstick test, used to diagnose severe PE (NICE definition) at
predetermined thresholds
Assay Threshold
Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI)
Likelihood ratios (95% CI)
p-value for comparison with
the local laboratory’s SPCRa
LR+ LR– Sensitivity Specificity
Local laboratory – SPCR 30mg/mmol 94 (91 to 96) 57 (53 to 61) 2.18 (1.96 to 2.39) 0.11 (0.07 to 0.16) – –
Central laboratoryb – SPCR via the BZC assay 30 mg/mmol 93 (90 to 95) 61 (57 to 66) 2.41 (2.15 to 2.68) 0.11 (0.07 to 0.15) 0.68 0.012
Central laboratoryb – SPCR via the PGR assay 30 mg/mmol 95 (92 to 97) 56 (51 to 60) 2.14 (1.93 to 2.35) 0.09 (0.06 to 0.13) 0.30 0.47
Central laboratoryb – SACR 2mg/mmol 99 (98 to 100) 23 (20 to 27) 1.29 (1.23 to 1.35) 0.03 (0.00 to 0.07) < 0.0001 < 0.0001
POC – proteinuria dipstick test 1+ 98 (96 to 99) 20 (17 to 24) 1.22 (1.17 to 1.28) 0.11 (0.04 to 0.18) 0.001 < 0.0001
a From McNemar’s test.
b Central laboratory (Kent).
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rule-out tests for severe PE (NICE definition). From Tables 10–13 the negative predictive values of each of the
three SPCR tests was 92–93% (98% for the SACR test), so a negative result from one of these tests brings the
risk of developing severe PE down to 7–8% (2% for the SACR test), compared with the pre-test risk of 43%.
Because we used a cut-off point for SACR of 2 mg/mmol based on published work in pregnancy,16 and we
note that this is different from the cut-off point chosen in other clinical contexts, we performed a further
analysis to examine whether or not a different cut-off point for SACR would have calibrated better with a
cut-off point of 30 mg/mmol for SPCR, and to show how an alternative choice of cut-off point for the
SPCR test would have affected sensitivity and specificity of these assays. Exploratory analyses are presented
in Tables 15 and 16 for different cut-off points. These analyses suggest that a cut-off point of 8 mg/mmol
for SACR achieves comparable diagnostic accuracy to a cut-off point of 30 mg/mmol for SPCR. Note that a
cut-off point of 3.5 mg/mmol has been suggested in other contexts.23
When overlain the ROC curves for the four assays were similar (Figure 2). The area under the central
laboratory’s SACR assay curve was significantly greater than that for the local laboratory’s SPCR test, although
the difference may not be of practical importance (0.02, 95% CI 0.01 to 0.04; p = 0.004) (Table 17).
Secondary analyses
Point-of-care dipstick test
The diagnostic accuracy of the POC urine proteinuria dipstick test at recruitment was investigated using a
prespecified threshold of 1+. Table 18 shows this index test result cross-tabulated against the reference
TABLE 15 Diagnostic accuracy of the three SPCR assays used to diagnose severe PE (NICE definition) at
different thresholds
Threshold
(mg/mmol)
Assay and sample (SPCR)
Local laboratory
Central laboratorya via the
BZC assay
Central laboratorya via the
PGR assay
Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI)
Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI)
Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI)
10 100 (99 to 100) 5 (3 to 7) 100 (99 to 100) 9 (7 to 12) 100 (99 to 100) 9 (6 to 11)
20 97 (96 to 99) 37 (32 to 41) 98 (96 to 99) 42 (38 to 46) 99 (97 to 100) 36 (32 to 40)
30 94 (91 to 96) 57 (53 to 61) 93 (91 to 95) 61 (57 to 66) 95 (93 to 97) 56 (52 to 60)
40 88 (85 to 91) 73 (69 to 77) 88 (85 to 91) 73 (69 to 77) 90 (87 to 93) 67 (63 to 71)
50 82 (78 to 85) 80 (76 to 83) 82 (78 to 85) 80 (76 to 83) 85 (81 to 88) 75 (71 to 79)
60 77 (73 to 81) 83 (79 to 86) 77 (73 to 81) 84 (81 to 87) 79 (75 to 83) 79 (76 to 83)
a Central laboratory (Kent).
TABLE 16 Diagnostic accuracy of the central laboratory’s (Kent) SACR assay used to diagnose severe PE (NICE
definition) at different thresholds
Threshold (mg/mmol) Sensitivity (%) (95% CI) Specificity (%) (95% CI)
1 100 (99 to 100) 7 (5 to 9)
2 99 (98 to 100) 23 (20 to 27)
3.5 99 (98 to 100) 35 (31 to 39)
8 96 (94 to 98) 57 (53 to 61)
16 89 (86 to 92) 73 (69 to 76)
RESULTS
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standard (NICE definition of severe PE). Sensitivity, specificity, LR+s and LR–s are shown in Table 14.
As expected, the urine proteinuria dipstick at this threshold had high sensitivity (98%, 95% CI 96% to
99%) but low specificity (20%, 95% CI 17% to 24%).
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FIGURE 2 Receiver operating characteristic curves for the four assays of the recruitment urine sample used to
diagnose severe PE (NICE definition).
TABLE 18 Cross-tabulation of the POC proteinuria dipstick test at recruitment (threshold 1+) against severe PE
(NICE definition)
Threshold
Number of women
Without severe PE With severe PE Total
Trace 108 9 117
1+ or higher 434 408 842
Total 542 417 959
TABLE 17 Areas under ROC curves for the four assays of the recruitment urine sample used to diagnose severe PE
(NICE definition)
Assay Area under ROC curve (95% CI)
Comparison with the local
laboratory’s SPCR
Difference (95% CI) p-valuea
Local laboratory – SPCR 0.87 (0.84 to 0.89) – –
Central laboratoryb – SPCR via the BZC assay 0.88 (0.86 to 0.90) 0.02 (0.00 to 0.03) 0.057
Central laboratoryb – SPCR via the PGR assay 0.88 (0.85 to 0.90) 0.01 (0.00 to 0.03) 0.17
Central laboratoryb – SACR 0.89 (0.87 to 0.91) 0.02 (0.01 to 0.04) 0.004
a Using the non-parametric method of DeLong et al.21
b Central laboratory (Kent).
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Proteinuria as reference standard
The diagnostic accuracy of the four assays using the spot urine sample at recruitment were compared
using prespecified thresholds of 30 mg/mmol for SPCR and 2 mg/mmol for SACR. Tables 19–22 show
index test results cross-tabulated against the reference standard (proteinuria). Sensitivities, specificities,
LR+s and LR–s are shown in Table 23. The three SPCR tests all had sensitivity in excess of 90% at the
TABLE 19 Cross-tabulation of the local laboratory’s SPCR testing of the recruitment urine sample (threshold
30mg/mmol) against proteinuria
Threshold (mg/mmol)
Number of women
Without proteinuria With proteinuriaa Total
< 30 302 34 336
≥ 30 182 441 623
Total 484 475 959
a ≥ 300mg/l using the central laboratory’s BZC assay of the 24-hour urine sample.
TABLE 22 Cross-tabulation of the central laboratory’s (Kent) SACR testing of the recruitment urine sample
(threshold 2mg/mmol) against proteinuria
Threshold (mg/mmol)
Number of women
Without proteinuria With proteinuriaa Total
< 2 125 4 129
≥ 2 359 471 830
Total 484 475 959
a ≥ 300mg/l using the central laboratory’s BZC assay of the 24-hour urine sample.
TABLE 20 Cross-tabulation of the central laboratory’s (Kent) SPCR testing of the recruitment urine sample using
the BZC assay (threshold 30mg/mmol) against proteinuria
Threshold (mg/mmol)
Number of women
Without proteinuria With proteinuriaa Total
< 30 328 34 362
≥ 30 156 441 597
Total 484 475 959
a ≥ 300mg/l using the central laboratory’s BZC assay of the 24-hour urine sample.
TABLE 21 Cross-tabulation of the central laboratory’s (Kent) SPCR testing of the recruitment urine sample using
the PGR assay (threshold 30mg/mmol) against proteinuria
Threshold (mg/mmol)
Number of women
Without proteinuria With proteinuriaa Total
< 30 300 24 324
≥ 30 184 451 635
Total 484 475 959
a ≥ 300mg/l using the central laboratory’s BZC assay of the 24-hour urine sample.
RESULTS
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TABLE 23 Diagnostic accuracy of the four assays of the recruitment urine sample used to diagnose proteinuria at predetermined thresholds
Assay
Threshold
(mg/mmol)
Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI)
Likelihood ratios (95% CI)
p-value for the comparison with
the local laboratory’s SPCRa
LR+ LR– Sensitivity Specificity
Local laboratory – SPCR 30 93 (90 to 95) 62 (58 to 67) 2.47 (2.18 to 2.76) 0.11 (0.08 to 0.15) – –
Central laboratoryb – SPCR via the BZC assay 30 93 (90 to 95) 68 (63 to 72) 2.88 (2.50 to 3.26) 0.11 (0.07 to 0.14) 1.00 0.006
Central laboratoryb – SPCR via the PGR assay 30 95 (92 to 97) 56 (51 to 60) 2.14 (1.93 to 2.35) 0.09 (0.06 to 0.13) 0.068 0.83
Central laboratoryb – SACR 2 99 (98 to 100) 23 (20 to 27) 1.29 (1.23 to 1.35) 0.03 (0.00 to 0.07) < 0.0001 < 0.0001
a From McNemar’s test.
b Central laboratory (Kent).
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prespecified thresholds. The central laboratory’s SACR test had significantly higher sensitivity (99%, 95% CI
98% to 100%) than the local laboratory’s SPCR test, but its specificity (26%, 95% CI 22% to 30%) was
significantly lower. The high sensitivities and LR–s of ≤ 0.1 suggest that all of the tests could be used as
rule-out tests for proteinuria.
When overlain the ROC curves for the four assays were, again, similar (Figure 3). The areas under the
central laboratory’s SACR curve and the central laboratory’s SPCR BZC assay curve were both significantly
greater than that for the local laboratory’s SPCR curve, although the differences may not be of practical
importance (Table 24).
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FIGURE 3 Receiver operating characteristic curves for the four assays of the recruitment urine sample used to
diagnose proteinuria.
TABLE 24 Areas under ROC curves for four assays of recruitment urine sample used to diagnose proteinuria
Assay Area under ROC curve (95% CI)
Comparison with the local
laboratory’s SPCR
Difference (95% CI) p-valuea
Local laboratory – SPCR 0.90 (0.88 to 0.92) – –
Central laboratoryb – SPCR via the BZC assay 0.91 (0.90 to 0.93) 0.02 (0.00 to 0.03) 0.047
Central laboratoryb – SPCR via the PGR assay 0.91 (0.89 to 0.93) 0.01 (0.00 to 0.03) 0.17
Central laboratoryb – SACR 0.92 (0.91 to 0.94) 0.02 (0.01 to 0.04) 0.002
a Using the non-parametric method of DeLong et al.21
b Central laboratory (Kent).
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Severe pre-eclampsia (clinician diagnosis) as the reference standard
The diagnostic accuracy of the four assays using the spot urine sample at recruitment, and two assays using
the 24-hour urine sample, were compared using prespecified thresholds of 30 mg/mmol for SPCR and
2 mg/mmol for SACR. Tables 25–30 show index test results cross-tabulated against the reference standard
(clinician diagnosis of severe PE). Sensitivities, specificities, and LR+s and LR–s are shown in Table 31.
The three SPCR tests and two SPCR tests all had sensitivity below 90% at the prespecified thresholds.
The central laboratory’s SACR test from the recruitment sample had a significantly higher sensitivity (97%,
95% CI 93% to 99%) than the local laboratory’s SPCR test from the recruitment sample, but its specificity
(16%, 95% CI 14% to 19%) was significantly lower.
TABLE 26 Cross-tabulation of the central laboratory’s (Kent) SPCR testing of the recruitment urine sample using
the BZC assay (threshold 30mg/mmol) against severe PE (clinician diagnosis)
Threshold (mg/mmol)
Number of women
Without severe PE With severe PEa Total
< 30 331 31 362
≥ 30 435 162 597
Total 766 193 959
a Severe PET protocol and/or magnesium sulphate treatment given.
TABLE 27 Cross-tabulation of the central laboratory’s (Kent) SPCR testing of the recruitment urine sample using
the PGR assay (threshold 30mg/mmol) against severe PE (clinician diagnosis)
Threshold (mg/mmol)
Number of women
Without severe PE With severe PEa Total
< 30 296 28 324
≥ 30 470 165 635
Total 766 193 959
a Severe PET protocol and/or magnesium sulphate treatment given.
TABLE 25 Cross-tabulation of the local laboratory’s (Kent) SPCR testing of the recruitment urine sample (threshold
30mg/mmol) against severe PE (clinician diagnosis)
Threshold (mg/mmol)
Number of women
Without severe PE With severe PEa Total
< 30 308 28 336
≥ 30 458 165 623
Total 766 193 959
a Severe PET protocol and/or magnesium sulphate treatment given.
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When overlain the ROC curves for the six assays were similar and demonstrated a much poorer diagnostic
accuracy compared with the NICE definition of PE as the reference standard (Figure 4). The areas under
the central laboratory’s SACR (recruitment sample) curve, the central laboratory’s SPCR via the BZC assay
(24-hour sample) curve and the central laboratory’s SPCR via the PGR assay (24-hour) curve were all
significantly greater than that for the local laboratory’s SPCR curve, although the differences may not be
of practical importance (Table 32).
The diagnostic accuracy of the POC urine proteinuria dipstick test at recruitment was also investigated
using a prespecified threshold of 1+. Table 33 shows this index test result cross-tabulated against the
reference standard (severe PE, clinician diagnosis). Sensitivity, specificity, LR+s and LR–s are shown in
Table 31. As expected, the urine proteinuria dipstick at this threshold had high sensitivity (92%, 95% CI
88% to 96%) but low specificity (13%, 95% CI 11% to 16%).
TABLE 29 Cross-tabulation of the central laboratory’s (Kent) SPCR testing of the 24-hour urine sample using the
BZC assay (threshold 30mg/mmol) against severe PE (clinician diagnosis)
Threshold (mg/mmol)
Number of women
Without severe PE With severe PEa Total
< 30 338 32 370
≥ 30 428 161 589
Total 766 193 959
a Severe PET protocol and/or magnesium sulphate treatment given.
TABLE 30 Cross-tabulation of the central laboratory’s (Kent) SPCR testing of the 24-hour urine sample using the
PGR assay (threshold 30mg/mmol) against severe PE (clinician diagnosis)
Threshold (mg/mmol)
Number of women
Without severe PE With severe PEa Total
< 30 300 31 331
≥ 30 466 162 628
Total 766 193 959
a Severe PET protocol and/or magnesium sulphate treatment given.
TABLE 28 Cross-tabulation of the central laboratory’s (Kent) SACR testing of the recruitment urine sample
(threshold 2mg/mmol) against severe PE (clinician diagnosis)
Threshold (mg/mmol)
Number of women
Without severe PE With severe PEa Total
< 2 123 6 129
≥ 2 643 187 830
Total 766 193 959
a Severe PET protocol and/or magnesium sulphate treatment given.
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TABLE 31 Diagnostic accuracy of the four assays of the recruitment urine sample and the two assays of the 24-hour urine sample used to diagnose severe PE (clinician
diagnosis) at predetermined thresholds
Assay and sample Threshold
Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI)
Likelihood ratios (95% CI)
p-value for comparison with
the local laboratory’s SPCRa
LR+ LR– Sensitivity Specificity
Recruitment sample
Local laboratory – SPCR 30mg/mmol 85 (80 to 90) 40 (37 to 44) 1.43 (1.31 to 1.55) 0.36 (0.23 to 0.49) – –
Central laboratoryb – SPCR via the
BZC assay
30 mg/mmol 84 (78 to 89) 43 (40 to 47) 1.48 (1.35 to 1.61) 0.37 (0.25 to 0.50) 0.44 0.022
Central laboratoryb – SPCR via the
PGR assay
30 mg/mmol 85 (80 to 90) 39 (35 to 42) 1.39 (1.28 to 1.51) 0.38 (0.24 to 0.51) 1.00 0.23
Central laboratoryb – SACR 2mg/mmol 97 (93 to 99) 16 (14 to 19) 1.15 (1.11 to 1.20) 0.19 (0.04 to 0.35) < 0.0001 < 0.0001
24-hour sample
Central laboratoryb – SPCR via the
BZC assay
30 mg/mmol 83 (77 to 88) 44 (41 to 48) 1.49 (1.36 to 1.63) 0.38 (0.25 to 0.50) 0.37 0.010
Central laboratoryb – SPCR via the
PGR assay
30 mg/mmol 84 (78 to 89) 39 (36 to 43) 1.38 (1.26 to 1.50) 0.41 (0.27 to 0.55) 0.47 0.48
POC – proteinuria dipstick test 1+ 92 (88 to 96) 13 (11 to 16) 1.06 (1.01 to 1.12) 0.58 (0.28 to 0.89) 0.012 < 0.0001
a From McNemar’s test.
b Central laboratory (Kent).
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FIGURE 4 Receiver operating characteristic curves for the four assays of the recruitment urine sample and the two
assays of the 24-hour urine sample used to predict severe PE (clinician diagnosis).
TABLE 32 Areas under ROC curves for the four assays of the recruitment urine sample and the two assays of the
24-hour urine sample used to predict severe PE (clinician diagnosis)
Assay and sample
Area under ROC curve
(95% CI)
Comparison with the local laboratory’s SPCR
Difference (95% CI) p-valuea
Recruitment sample
Local laboratory – SPCR 0.70 (0.66 to 0.74) – –
Central laboratoryb – SPCR via the
BZC assay
0.72 (0.68 to 0.76) 0.02 (0.00 to 0.04) 0.11
Central laboratoryb – SPCR via the
PGR assay
0.71 (0.67 to 0.75) 0.01 (–0.01 to 0.03) 0.25
Central laboratoryb – SACR 0.72 (0.68 to 0.76) 0.02 (0.00 to 0.04) 0.028
24-hour sample
Central laboratoryb – SPCR via the
BZC assay
0.74 (0.70 to 0.78) 0.03 (0.01 to 0.06) 0.006
Central laboratoryb – SPCR via the
PGR assay
0.73 (0.69 to 0.77) 0.03 (0.01 to 0.05) 0.012
a Using the non-parametric method of DeLong et al.21
b Central laboratory (Kent).
TABLE 33 Cross-tabulation of the POC proteinuria dipstick test at recruitment (threshold of 1+) against severe PE
(NICE definition)
Threshold
Number of women
Without severe PEa With severe PEa Total
Trace 102 15 117
‘1+’ or higher 664 178 842
Total 766 193 959
a Severe PET protocol and/or magnesium sulphate treatment given.
RESULTS
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Prediction of adverse perinatal outcomes
The accuracy of the four assays using the spot urine sample at recruitment and the two assays using the
24-hour urine sample in predicting adverse perinatal outcomes were compared using prespecified
thresholds of 30 mg/mmol for SPCR and 2 mg/mmol for SACR. Tables 34–39 show index test results
cross-tabulated against adverse perinatal outcome. Sensitivities, specificities, LR+s and LR–s are shown in
Table 40. The three SPCR tests and two SPCR tests all had sensitivity below 80% at the prespecified
thresholds. The central laboratory’s SACR test from the recruitment sample had significantly higher
sensitivity (94%, 95% CI 84% to 98%) than the local laboratory’s SPCR test from the recruitment sample,
but its specificity (14%, 95% CI 12% to 16%) was significantly lower. The central laboratory’s SPCR test
via the PGR assay also had significantly higher sensitivity (79%, 95% CI 67% to 88%) than the local
laboratory’s SPCR test.
TABLE 34 Cross-tabulation of the local laboratory’s (Kent) SPCR testing of the recruitment urine sample (threshold
30mg/mmol) against perinatal adverse outcome
Threshold (mg/mmol)
Number of women
Without adverse perinatal outcome With adverse perinatal outcome Total
< 30 317 19 336
≥ 30 580 43 623
Total 897 62 959
TABLE 35 Cross-tabulation of the central laboratory’s (Kent) SPCR testing of the recruitment urine sample using
the BZC assay (threshold 30mg/mmol) against perinatal adverse outcome
Threshold (mg/mmol)
Number of women
Without adverse perinatal outcome With adverse perinatal outcome Total
< 30 348 14 362
≥ 30 549 48 597
Total 897 62 959
TABLE 36 Cross-tabulation of the central laboratory’s (Kent) SPCR testing of the recruitment urine sample using
the PGR assay (threshold 30mg/mmol) against perinatal adverse outcome
Threshold (mg/mmol)
Number of women
Without adverse perinatal outcome With adverse perinatal outcome Total
< 30 311 13 324
≥ 30 586 49 635
Total 897 62 959
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The ROC curves for all six assays demonstrated poor diagnostic accuracy (Figure 5), although the areas
under the central laboratory’s SPCR via the BZC assay (recruitment sample) curve, the central laboratory’s
SPCR via the PGR assay (recruitment sample) curve and the central laboratory’s SACR (recruitment sample)
curve were all significantly greater than that for the local laboratory’s SPCR (recruitment sample) curve
(Table 41).
Because of missing data, only 530 women could be included in the analyses involving the central
laboratory’s BZC assay of the delivery spot urine samples (i.e. the increase from recruitment to delivery and
the maximum of the recruitment and delivery laboratory BZC SPCR assay). ROC curves for the prediction of
adverse perinatal outcomes are shown in Figure 6, alongside that for the recruitment sample central
laboratory’s SPCR test via the BZC assay for comparison. Neither the increase nor the maximum offered
any improvement over the original recruitment sample in the prediction of adverse perinatal outcomes
(Table 42).
TABLE 38 Cross-tabulation of the central laboratory’s SPCR testing of the 24-hour urine sample using the BZC assay
(threshold 30mg/mmol) against perinatal adverse outcome
Threshold (mg/mmol)
Number of women
Without adverse perinatal outcome With adverse perinatal outcome Total
< 30 350 20 370
≥ 30 547 42 589
Total 897 62 959
TABLE 39 Cross-tabulation of central laboratory’s (Kent) SPCR testing of the 24-hour urine sample using the PGR
assay (threshold 30mg/mmol) against perinatal adverse outcome
Threshold (mg/mmol)
Number of women
Without adverse perinatal outcome With adverse perinatal outcome Total
< 30 313 18 331
≥ 30 584 44 628
Total 897 62 959
TABLE 37 Cross-tabulation of the central laboratory’s (Kent) SACR testing of the recruitment urine sample
(threshold 2mg/mmol) against perinatal adverse outcome
Threshold (mg/mmol)
Number of women
Without adverse perinatal outcome With adverse perinatal outcome Total
< 2 125 4 129
≥ 2 772 58 830
Total 897 62 959
RESULTS
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TABLE 40 Diagnostic accuracy of the four assays of the recruitment urine sample and the two assays of the 24-hour urine sample used to predict adverse perinatal outcome at
predetermined thresholds
Assay and sample
Threshold
(mg/mmol)
Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI)
Likelihood ratios (95% CI)
p-value for comparison with
the local laboratory’s SPCRa
LR+ LR– Sensitivity Specificity
Recruitment sample
Local laboratory – SPCR 30 69 (56 to 80) 35 (32 to 39) 1.07 (0.89 to 1.26) 0.87 (0.53 to 1.20) – –
Central laboratoryb – SPCR via the
BZC assay
30 77 (65 to 87) 39 (36 to 42) 1.26 (1.08 to 1.45) 0.58 (0.31 to 0.85) 0.059 0.003
Central laboratoryb – SPCR via the
PGR assay
30 79 (67 to 88) 35 (32 to 38) 1.21 (1.04 to 1.38) 0.60 (0.31 to 0.90) 0.034 0.56
Central laboratoryb – SACR 2 94 (84 to 98) 14 (12 to 16) 1.09 (1.01 to 1.16) 0.46 (0.02 to 0.91) < 0.0001 < 0.0001
24-hour sample
Central laboratoryb – SPCR via the
BZC assay
30 68 (55 to 79) 39 (36 to 42) 1.11 (0.91 to 1.31) 0.83 (0.52 to 1.13) 0.74 0.006
Central laboratoryb – SPCR via the
PGR assay
30 71 (58 to 82) 35 (32 to 38) 1.09 (0.91 to 1.27) 0.83 (0.50 to 1.16) 0.74 0.73
a From McNemar’s test.
b Central laboratory (Kent).
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Subgroup analysis
The primary analysis was repeated in the subset of women with 1+ or higher on the POC dipstick test.
Tables 43–46 show index test results cross-tabulated against the reference standard (NICE definition
of severe PE). Sensitivities, specificities, LR+s and LR–s are shown in Table 47. The three SPCR tests all
had sensitivity in excess of 90% at the prespecified thresholds, but with poor specificity. The central
laboratory’s SACR test had significantly higher sensitivity (99%, 95% CI 98% to 100%) than the local
laboratory’s SPCR test, but its specificity (20%, 95% CI 16% to 24%) was significantly lower. The high
sensitivities and LR–s of ≤ 0.1 suggest that all of the tests could be used as rule-out tests for severe PE
(NICE definition) in the subgroup with 1+ or higher on the POC dipstick test.
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FIGURE 5 Receiver operating characteristic curves for the four assays of the recruitment urine sample and the two
assays of the 24-hour urine sample used to predict adverse perinatal outcome.
TABLE 41 Areas under ROC curves for the four assays of the recruitment urine sample and the two assays of the
24-hour urine sample used to predict adverse perinatal outcome
Assay and sample
Area under ROC curve
(95% CI)
Comparison with the local
laboratory’s SPCR
Difference (95% CI) p-valuea
Recruitment sample
Local laboratory – SPCR 0.59 (0.51 to 0.67) – –
Central laboratoryb – SPCR via the BZC assay 0.64 (0.56 to 0.71) 0.05 (0.01 to 0.08) 0.025
Central laboratoryb – SPCR via the PGR assay 0.63 (0.56 to 0.70) 0.04 (0.00 to 0.08) 0.047
Central laboratoryb – SACR 0.63 (0.56 to 0.71) 0.04 (0.00 to 0.04) 0.039
24-hour sample
Central laboratoryb – SPCR via the BZC assay 0.60 (0.52 to 0.68) 0.01 (–0.03 to 0.06) 0.64
Central laboratoryb – SPCR via the PGR assay 0.60 (0.52 to 0.68) 0.03 (–0.03 to 0.06) 0.58
a Using the non-parametric method of DeLong et al.21
b Central laboratory (Kent).
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
32
0
0
20
40
60
80
100
20 40 60 80 100
1 – specificity (%)
Se
n
si
ti
vi
ty
 (
%
)
Central laboratory – SPCR 
via the BZC assay: recruitment 
sample
Central laboratory – SPCR
via the BZC assay: increase 
from recruitment to delivery
Central laboratory – SPCR
via the BZC assay: maximum 
of recruitment and delivery
FIGURE 6 Receiver operating characteristic curves for the increase from recruitment to delivery for the BZC SPCR
assay, and maximum of recruitment and delivery BZC SPCR assay, in the prediction of adverse perinatal outcome.
TABLE 42 Areas under ROC curves for the increase from recruitment to delivery BZC SPCR assay, and maximum of
recruitment and delivery BZC SPCR assay, in the prediction of adverse perinatal outcome
Assay
Area under ROC curve
(95% CI)
Comparison with the recruitment
sample of the central laboratory’s
SPCR test via the BZC assay
Difference (95% CI) p-valuea
Recruitment sampleb 0.64 (0.53 to 0.75) – –
Increase from recruitment to delivery sampleb 0.53 (0.41 to 0.66) –0.11 (–0.27 to 0.05) 0.19
Maximum of recruitment and delivery sampleb 0.63 (0.52 to 0.74) –0.01 (–0.06 to 0.04) 0.71
a Using the non-parametric method of DeLong et al.21
b Central laboratory’s (Kent) SPCR test via the BZC assay.
TABLE 43 Cross-tabulation of the local laboratory’s SPCR testing of the recruitment urine sample (threshold
30mg/mmol) against severe PE (NICE definition), in the subgroup with 1+ or higher on the POC dipstick test
Threshold (mg/mmol)
Number of women
Without severe PE With severe PE Total
< 30 228 24 252
≥ 30 206 384 590
Total 434 408 842
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When overlain the ROC curves for the four assays were similar (Figure 7). The area under the central
laboratory’s SACR curve was significantly greater than that for the local laboratory’s SPCR curve, although
the difference (0.02, 95% CI 0.00 to 0.04; p = 0.012) may not be of practical importance (Table 48).
The same subgroup analysis (1+ or higher on the POC dipstick test) was repeated using clinician diagnosis
of severe PE as the reference standard and including the two assays of the 24-hour urine sample as index
tests. Tables 49–54 show index test results cross-tabulated against the reference standard. Sensitivities,
TABLE 45 Cross-tabulation of the central laboratory’s (Kent) SPCR testing of the recruitment urine sample using
the PGR assay (threshold 30mg/mmol) against severe PE (NICE definition), in the subgroup with 1+ or higher on
the POC dipstick test
Threshold (mg/mmol)
Number of women
Without severe PE With severe PE Total
< 30 219 20 239
≥ 30 215 388 603
Total 434 408 842
TABLE 44 Cross-tabulation of the central laboratory’s (Kent) SPCR testing of the recruitment urine sample using
the BZC assay (threshold 30mg/mmol) against severe PE (NICE definition), in the subgroup with 1+ or higher on
the POC dipstick test
Threshold (mg/mmol)
Number of women
Without severe PE With severe PE Total
< 30 253 26 279
≥ 30 181 382 563
Total 434 408 842
TABLE 46 Cross-tabulation of the central laboratory’s (Kent) SACR testing of the recruitment urine sample
(threshold 2mg/mmol) against severe PE (NICE definition), in the subgroup with 1+ or higher on the POC
dipstick test
Threshold (mg/mmol)
Number of women
Without severe PE With severe PE Total
< 2 86 3 89
≥ 2 348 405 753
Total 434 408 842
RESULTS
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TABLE 47 Diagnostic accuracy of the four assays of the recruitment urine sample used to diagnose severe PE (NICE definition) at predetermined thresholds, in the subgroup
with 1+ or higher on the POC dipstick test
Assay
Threshold
(mg/mmol)
Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI)
Likelihood ratios (95% CI)
p-value for the comparison with
the local laboratory’s SPCRa
LR+ LR– Sensitivity Specificity
Local laboratory – SPCR 30 94 (91 to 96) 53 (48 to 57) 1.98 (1.78 to 2.19) 0.11 (0.07 to 0.16) – –
Central laboratoryb – SPCR via the
BZC assay
30 94 (91 to 96) 58 (54 to 63) 2.25 (1.99 to 2.50) 0.11 (0.07 to 0.15) 0.67 0.003
Central laboratoryb – SPCR via the
PGR assay
30 95 (93 to 97) 50 (46 to 55) 1.92 (1.73 to 2.11) 0.10 (0.05 to 0.14) 0.39 0.31
Central laboratoryb – SACR 2 99 (98 to 100) 20 (16 to 24) 1.24 (1.18 to 1.30) 0.04 (–0.01 to 0.08) < 0.0001 < 0.0001
a From McNemar’s test.
b Central laboratory (Kent).
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FIGURE 7 Receiver operating characteristic curves for the four assays of the recruitment urine sample used to
diagnose severe PE (NICE definition), in the subgroup with 1+ or higher on the POC dipstick test.
TABLE 48 Areas under ROC curves for the four assays of the recruitment urine sample used to diagnose severe PE
(NICE definition), in the subgroup with 1+ or higher on the POC dipstick test
Assay
Area under ROC curve
(95% CI)
Comparison with the local
laboratory’s SPCR
Difference (95% CI) p-valuea
Local laboratory – SPCR 0.85 (0.83 to 0.88) – –
Central laboratoryb – SPCR via the BZC assay 0.87 (0.85 to 0.89) 0.02 (0.00 to 0.03) 0.074
Central laboratoryb – SPCR via the PGR assay 0.86 (0.84 to 0.89) 0.01 (–0.01 to 0.03) 0.31
Central laboratoryb – SACR 0.88 (0.85 to 0.90) 0.03 (0.00 to 0.04) 0.012
a Using the non-parametric method of DeLong et al.21
b Central laboratory (Kent).
TABLE 49 Cross-tabulation of the local laboratory’s (Kent) SPCR testing of the recruitment urine sample (threshold
30mg/mmol) against severe PE (clinician diagnosed), in the subgroup with 1+ or higher on the POC dipstick test
Threshold (mg/mmol)
Number of women
Without severe PE With severe PEa Total
< 30 232 20 252
≥ 30 432 158 590
Total 664 178 842
a Severe PET protocol and/or magnesium sulphate treatment given.
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TABLE 53 Cross-tabulation of the central laboratory’s (Kent) SPCR testing of the 24-hour urine sample using the
BZC assay (threshold 30mg/mmol) against severe PE (clinician diagnosed), in the subgroup with 1+ or higher on
the POC dipstick test
Threshold (mg/mmol)
Number of women
Without severe PE With severe PEa Total
< 30 257 26 283
≥ 30 407 152 559
Total 664 178 842
a Severe PET protocol and/or magnesium sulphate treatment given.
TABLE 51 Cross-tabulation of the central laboratory’s (Kent) SPCR testing of the recruitment urine sample using
the PGR assay (threshold 30mg/mmol) against severe PE (clinician diagnosed), in the subgroup with 1+ or higher
on the POC dipstick test
Threshold (mg/mmol)
Number of women
Without severe PE With severe PEa Total
< 30 216 23 239
≥ 30 448 155 603
Total 664 178 842
a Severe PET protocol and/or magnesium sulphate treatment given.
TABLE 52 Cross-tabulation of the central laboratory’s (Kent) SACR testing of the recruitment urine sample
(threshold 2mg/mmol) against severe PE (clinician diagnosed), in the subgroup with 1+ or higher on the POC
dipstick test
Threshold (mg/mmol)
Number of women
Without severe PE With severe PEa Total
< 2 84 5 89
≥ 2 580 173 753
Total 664 178 842
a Severe PET protocol and/or magnesium sulphate treatment given.
TABLE 50 Cross-tabulation of the central laboratory’s (Kent) SPCR testing of the recruitment urine sample using
the BZC assay (threshold 30mg/mmol) against severe PE (clinician diagnosed), in the subgroup with 1+ or higher
on the POC dipstick test
Threshold (mg/mmol)
Number of women
Without severe PE With severe PEa Total
< 30 254 25 279
≥ 30 410 153 563
Total 434 178 842
a Severe PET protocol and/or magnesium sulphate treatment given.
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specificities, LR+s and LR–s are shown in Table 55. The three SPCR tests from the recruitment urine sample
and two SPCR tests from the 24-hour sample had sensitivity in excess of 80% but below 90% at the
prespecified thresholds, and with poor specificity. The central laboratory’s SACR test had significantly
higher sensitivity (97%, 95% CI 94% to 99%) than the local laboratory’s SPCR test, but its specificity
(13%, 95% CI 10% to 15%) was significantly lower.
The ROC curves for all six assays demonstrated poor diagnostic accuracy (Figure 8), although the areas
under the central laboratory’s SACR (recruitment sample) curve and the central laboratory’s SPCR test via
the BZC assay (24-hour sample) curve (Figure 9) curve were both significantly greater than that for the
local laboratory’s SPCR (recruitment sample) curve (Table 56).
Laboratory assay method for 24-hour proteinuria
The percentage of women with proteinuria (≥ 300 mg/24 hours) defined using the central laboratory’s
(Kent) PGR assay (55%) was greater than the percentage defined using the BZC assay (50%) (Table 57).
Consequently, the percentage of women categorised as having severe PE according to the NICE definition
was greater using the alternative PGR assay (48%) than using the BZC assay (43%) (Table 58).
The diagnostic accuracy of the four assays using the spot urine sample at recruitment were compared using
prespecified thresholds of 30 mg/mmol for SPCR and 2mg/mmol for SACR, but using the PGR assay instead of
the BZC assay in the NICE definition of severe PE. Tables 59–62 show index test results cross-tabulated against
this alternative reference standard. Sensitivities, specificities, LR+s and LR–s are shown in Table 63. The three
SPCR tests all had sensitivity in excess of 90% at the prespecified thresholds but with poor specificity. The
central laboratory’s SACR test had significantly higher sensitivity (99%, 95% CI 97% to 100%) than the local
laboratory’s SPCR test, but its specificity (25%, 95% CI 21% to 29%) was significantly lower. LR–s were
slightly higher than those found using the BZC assay in the proteinuria component of the definition.
When overlain, the ROC curves for the four assays were similar (see Figure 9). The areas under the curve
for all three laboratory assays were significantly greater than that for the local laboratory’s SPCR curve,
although the differences may not be of practical importance (Table 64).
Further investigation of the agreement between the central laboratory’s (Kent) BZC and PGR assays of total
protein from the 24-hour urine sample was conducted for 1446 women with data from both assays. The
minimum protein concentration was 68 mg/l for the BZC assay and 26 mg/l for the PGR assay. Maximum
values were of the order of 45,000 mg/l for both assays. Figure 10 shows a Bland–Altman plot for the two
assays (for the difference between the BZC assay and the PGR assay plotted against the average of the
two). There was a distinctly non-linear relationship between the two. As the clinical decision point in
relation to diagnosing severe PE is 300 mg/l, we have shown this relationship over a limited range of values
for the average between 0 mg/l and 2000 mg/l. Up to values of around 1200 mg/l the PGR assay value is
typically higher than the BZC assay value (at 600 mg/l the difference averages around 100 mg/l), and at
values from 1200 to 2000 mg/l the PGR assay value is typically smaller.
TABLE 54 Cross-tabulation of the central laboratory’s (Kent) SPCR testing of the 24-hour urine sample using the
PGR assay (threshold 30mg/mmol) against severe PE (clinician diagnosed), in the subgroup with 1+ or higher on
the POC dipstick test
Threshold (mg/mmol)
Number of women
Without severe PE With severe PEa Total
< 30 219 26 245
≥ 30 445 152 597
Total 664 178 842
a Severe PET protocol and/or magnesium sulphate treatment given.
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TABLE 55 Diagnostic accuracy of the four assays of the recruitment urine sample and the two assays of the 24-hour sample used to diagnose severe PE (clinician diagnosis) at
predetermined thresholds, in the subgroup with 1+ or higher on POC dipstick test
Assay and sample
Threshold
(mg/mmol)
Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI)
Likelihood ratios (95% CI)
p-value for the comparison
with local laboratory’s SPCRa
LR+ LR– Sensitivity Specificity
Recruitment sample
Local laboratory – SPCR 30 89 (83 to 93) 35 (31 to 39) 1.36 (1.26 to 1.47) 0.32 (0.18 to 0.46) – –
Central laboratoryb – SPCR via the
BZC assay
30 86 (80 to 91) 38 (35 to 42) 1.39 (1.27 to 1.51) 0.37 (0.23 to 0.51) 0.13 0.016
Central laboratoryb – SPCR via the
PGR assay
30 87 (81 to 92) 33 (29 to 36) 1.29 (1.19 to 1.39) 0.40 (0.24 to 0.56) 0.37 0.090
Central laboratoryb – SACR 2 97 (94 to 99) 13 (10 to 15) 1.11 (1.07 to 1.16) 0.22 (0.02 to 0.42) 0.0003 < 0.0001
24-hour sample
Central laboratoryb – SPCR via the
BZC assay
30 85 (79 to 90) 39 (35 to 43) 1.39 (1.27 to 1.51) 0.38 (0.24 to 1.52) 0.16 0.024
Central laboratoryb – SPCR via the
PGR assay
30 85 (79 to 90) 33 (29 to 37) 1.27 (1.17 to 1.38) 0.44 (0.28 to 1.61) 0.11 0.22
a From McNemar’s test.
b Central laboratory (Kent).
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FIGURE 8 Receiver operating characteristic curves for the four assays of the recruitment urine sample and the two
assays of the 24-hour sample used to diagnose severe PE (clinician diagnosis), in the subgroup with 1+ or higher on
POC dipstick test.
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FIGURE 9 Receiver operating characteristic curves for the four assays of the recruitment urine sample used to
diagnose severe PE (NICE definition, using the PGR assay).
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
40
TABLE 56 Areas under ROC curves for four assays of recruitment urine sample and two assays of 24-hour sample
used to diagnose severe PE (clinician diagnosis), in the subgroup with 1+ or higher on POC dipstick
Assay and sample
Area under ROC curve
(95% CI)
Comparison with the local
laboratory’s SPCR
Difference (95% CI) p-valuea
Recruitment sample
Local laboratory – SPCR 0.70 (0.66 to 0.74) – –
Central laboratoryb – SPCR via the BZC assay 0.71 (0.67 to 0.76) 0.01 (–0.01 to 0.03) 0.19
Central laboratoryb – SPCR via the PGR assay 0.71 (0.67 to 0.75) 0.01 (–0.01 to 0.03) 0.40
Central laboratoryb – SACR 0.72 (0.68 to 0.76) 0.02 (0.00 to 0.04) 0.042
24-hour sample
Central laboratoryb – SPCR via the BZC assay 0.73 (0.68 to 0.77) 0.03 (0.00 to 0.05) 0.040
Central laboratoryb – SPCR via the PGR assay 0.72 (0.68 to 0.77) 0.02 (0.00 to 0.05) 0.083
a Using the non-parametric method of DeLong et al.21
b Central laboratory (Kent).
TABLE 57 Women with proteinuria assessed using the central laboratory’s (Kent) testing of the 24-hour urine
sample using the BZC and PGR assays
Threshold (mg/mmol)
Number of women
PGR threshold (mg/l) Total
< 300 ≥ 300 –
< 300 425 59 484
≥ 300 2 473 475
Total 427 532 959
TABLE 58 Severe PE defined using the PGR assay in the proteinuria component (≥ 300mg/l from the 24-hour
sample) compared with definition using the BZC assay
Severe PE defined using the BZC assaya
Severe PE defined using the PGR assay,a number of women
Without severe PE With severe PE Total
Without severe PE 493 49 542
With severe PE 2 415 417
Total 495 464 959
a From central laboratory’s (Kent) testing of the 24-hour urine sample.
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TABLE 59 Cross-tabulation of the local laboratory’s (Kent) SPCR testing of the recruitment urine sample (threshold
30mg/mmol) against severe PE (NICE definition, using the PGR assay)
Threshold (mg/mmol)
Number of women
Without severe PE With severe PE Total
< 30 296 40 336
≥ 30 199 424 623
Total 495 464 959
TABLE 60 Cross-tabulation of the central laboratory’s (Kent) SPCR testing of the recruitment urine sample using
the BZC assay (threshold 30mg/mmol) against severe PE (NICE definition, using the PGR assay)
Threshold (mg/mmol)
Number of women
Without severe PE With severe PE Total
< 30 319 43 362
≥ 30 176 421 597
Total 495 464 959
TABLE 62 Cross-tabulation of the central laboratory’s (Kent) SACR testing of the recruitment urine sample
(threshold 2mg/mmol) against severe PE (NICE definition, using the PGR assay)
Threshold (mg/mmol)
Number of women
Without severe PE With severe PE Total
< 2 124 5 129
≥ 2 371 459 830
Total 495 464 959
TABLE 61 Cross-tabulation of the central laboratory’s (Kent) SPCR testing of the recruitment urine sample using
the PGR assay (threshold 30mg/mmol) against severe PE (NICE definition, using the PGR assay)
Threshold (mg/mmol)
Number of women
Without severe PE With severe PE Total
< 30 290 34 324
≥ 30 205 430 635
Total 495 464 959
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TABLE 63 Diagnostic accuracy of the four assays of the recruitment urine sample, and POC proteinuria dipstick test, used to diagnose severe PE (NICE definition, using the PGR
assay) at predetermined thresholds
Assay
Threshold
(mg/mmol)
Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI)
Likelihood ratios (95% CI)
p-value for the comparison with
the local laboratory’s SPCRa
LR+ LR– Sensitivity Specificity
Local laboratory – SPCR 30 91 (88 to 94) 60 (55 to 64) 2.27 (2.02 to 2.53) 0.14 (0.07 to 0.16) – –
Central laboratoryb – SPCR via the
BZC assay
30 91 (88 to 93) 64 (60 to 69) 2.55 (2.24 to 2.86) 0.14 (0.07 to 0.15) 0.59 0.013
Central laboratoryb – SPCR via the
PGR assay
30 93 (90 to 95) 59 (54 to 63) 2.24 (2.00 to 2.48) 0.13 (0.08 to 0.17) 0.27 0.52
Central laboratoryb – SACR 2 99 (97 to 100) 25 (21 to 29) 1.32 (1.25 to 1.39) 0.04 (0.00 to 0.08) < 0.0001 < 0.0001
a From McNemar’s test.
b Central laboratory (Kent).
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TABLE 64 Areas under ROC curves for the four assays of the recruitment urine sample used to diagnose severe PE
(NICE definition, using the PGR assay)
Assay
Area under ROC curve
(95% CI)
Comparison with the local
laboratory’s SPCR
Difference (95% CI) p-valuea
Local laboratory – SPCR 0.85 (0.82 to 0.87) – –
Central laboratoryb – SPCR via the BZC assay 0.87 (0.85 to 0.89) 0.02 (0.00 to 0.04) 0.033
Central laboratoryb – SPCR via the PGR assay 0.87 (0.84 to 0.89) 0.02 (0.00 to 0.03) 0.050
Central laboratoryb – SACR 0.88 (0.85 to 0.90) 0.03 (0.01 to 0.04) 0.002
a Using the non-parametric method of DeLong et al.21
b Central laboratory (Kent).
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FIGURE 10 Bland–Altman plot of the central laboratory’s BZC and PGR assay protein concentrations.
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Chapter 4 Health economics
Methods of economic evaluation
Aim of economic evaluation
The aim of the economic evaluation was to estimate the cost-effectiveness of six laboratory tests compared
with the local laboratory’s SPCR test for the diagnosis of severe PE in pregnant women treated in
obstetric units.
Design of economic evaluation
Comparators
The analysis estimated the economic consequences of the following tests:
l local laboratory’s SPCR test
l central laboratory’s (Kent) SPCR test using the BZC assay
l central laboratory’s (Kent) SPCR test using the PGR assay
l central laboratory’s (Kent) SACR test
l central laboratory’s (Kent) 24-hour urine protein concentration using the BZC assay
l central laboratory’s (Kent) 24-hour urine protein concentration using the PGR assay
l dipstick test only.
Population
The economic evaluation incorporated the results of the clinical study, which included women aged
≥ 16 years who were at > 20 weeks’ gestation with confirmed new hypertension (systolic BP of
≥ 140 mmHg and/or diastolic BP of ≥ 90 mmHg) and trace or greater of proteinuria on automated
dipstick urinalysis.
Perspective
The economic evaluation assumed a NHS cost perspective.
Time horizon
Relevant costs and outcomes of each comparator were examined over a lifetime horizon.
Discounting of costs and outcomes
All costs and outcomes accumulated in future years in the analysis were discounted at an annual rate of
3.5%, as recommended by Her Majesty’s Treasury.24
Model structure
A decision-analytic decision tree model was used to carry out a cost-effectiveness analysis of each test
compared with the baseline test (local laboratory SPCR). It combined information collected during the
clinical study with external sources for resource use, unit costs and utility parameters to quantify the
economic consequences of each test for both the mother and baby.
The analysis built on the hypertension in pregnancy models published in NICE’s CG107.1 Specifically, the
current study updated the model pathway for hypertension in pregnancy (listed in appendix I of the NICE
guideline1) and PE (in appendix J of the NICE guideline1). A focused search of the literature was conducted
to update key transition probabilities with evidence published since 2011 (the publication year of the NICE
guideline). All model costs were updated to 2014/15 year using published UK unit costs.
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Model components
The decision-analytic model combined the following elements:
1. A decision-tree model incorporated the outcome of each proposed test: true positive, false negative,
true negative and false positive. The diagnostic accuracy of each test was estimated from data collected
prospectively during the study period.
2. Each branch corresponding to the outcome of the test leads to a decision tree for the management of
the mother and baby in the antenatal and postnatal period.
i. Patients in the true-negative branch enter a pathway adapted from appendix I of the NICE
guideline.1 False positives follow through the same pathway, with the exception of an additional day
of hospital stay for additional tests to establish the case as a negative.
ii. True positives enter a pathway of treatment for severe PE (adapted from appendix J of the
NICE guideline).1
iii. False negatives were assumed to be treated as true negatives, apart from the following changes as
per the methods used in the NICE model:1 90% in emergency caesarean section, 5% assisted birth
and 5% normal birth. The probability of intensive care for PE is 5%. The effect of delayed diagnosis
of severe PE is a higher probability of adverse outcome during delivery and the need for intensive
treatment for the mother. The probability of neonatal high-dependency/intensive care is assumed to
be unchanged compared with true negatives.
3. The therapeutic pathway simulated the lifetime progression of the mother and baby until death, which
determined the QALY outcome.
Model states
The initial part of the model defined the diagnostic accuracy of each test and contained the following
nodes: negative, positive, true positive, true negative, false positive and false negative. This was followed by
the therapeutic pathway that contained the following nodes: spontaneous onset of birth, induced onset of
birth and planned caesarean. Spontaneous and induction onset had identical pathways, with the only
difference in the distribution of the type of birth: normal vaginal birth, assisted vaginal birth and emergency
caesarean. This was followed by hospital admission for complications for the mother: severe PE, no severe
PE, maternal high-dependency unit (HDU), maternal intensive care unit (ICU) and maternal ward. This was
followed by hospital admission for complications for the baby: neonatal normal care, neonatal HDU,
neonatal ICU, neonatal intensive care unit (NICU) or no admission for complications. All pathways led to the
mortality nodes, death of the mother and/or baby, which determined the QALY outcomes.
Model diagram
The structure of the first part of the model (diagnostic pathway) is illustrated in Figure 11 and the second
part of the model (therapeutic pathway) in Figure 12.
Figure 11 demonstrates the pathway in the diagnostic part of the model. All patients begin at the initial node
(pregnant with hypertension and trace/dipstick +1 urine protein). The model then assigns patients to one of
the comparator tests. The presence or absence of severe PE will determine the subsequent progression of
patients to the therapeutic pathway in Figure 12. Patients transition into pathways according to the outcome
of testing: severe PE (true positive, false negative) or normal care in gestational hypertension/PE (true negative,
false positive). The pathway in Figure 11 is demonstrated for the local laboratory’s SPCR test and is identical
for all tests. Differences in pathways will be determined by the diagnostic accuracy (sensitivity and specificity)
collected in the clinical study.
Figure 12 demonstrates the pathway in the therapeutic part of the model. All patients begin at the initial
node, according to the consequences of tests in Figure 11 (severe PE, moderate PE or gestational
hypertension). Subsequent progression determines the type of birth, maternal HDU/ICU admission as a
result of PE and neonatal HDU/ICU. Transition probabilities are derived from the NICE hypertension in
HEALTH ECONOMICS
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pregnancy guideline model.1 Patients accumulate cost of treatment up to the end of the pathway (discharge
from maternal ward/HDU/ICU/death). The mean cost per patient is added to the intervention cost and
QALYs estimated based on maternal and neonatal mortality rates in PE or gestational hypertension.
Sources of model inputs
Effectiveness of interventions
Transition probabilities for the initial part of the model were derived from the results of the statistical
analysis of the diagnostic accuracy of each comparator test in relation to the clinician diagnosis of severe
PE, which was determined by the presence of severe PET protocol and/or magnesium sulphate treatment.
The distribution of patients across diagnostic categories is summarised in Table 65.
Transition probabilities
Transition probabilities for the model were derived from three sources:
1. Transition probabilities in the first part of the model (outcomes of tests) were informed by data on
diagnostic accuracy of each test prospectively collected from patients.
2. The consequences of hypertension in pregnancy and PE on maternal and neonatal outcomes were
modelled using transition probabilities obtained from the adapted NICE hypertension in pregnancy
models (reported in appendix I and appendix J of the NICE guideline1).
3. Probability of death was derived from mortality figures based on the confidential enquiry into maternal
and child health25 and Douglas and Redman,26 used in the NHS model and reported in NICE’s CG107,
in appendix K.1
A summary of transition probabilities used in the model is included in Table 66.
Women with GH
and > trace
proteinuria using
dipstick
Local laboratory SPCR
Negative
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#
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True negative
True positive
False positive
False negative
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pLocalSPCR_FP
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Central laboratory SPCR PGR
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24-hour urine BZC
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FIGURE 11 Structure of diagnostic pathway in the decision-analytic model.
DOI: 10.3310/hta21610 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 61
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Waugh et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
47
Spontaneous onset
pSpontaneousPreecl
Assisted vaginal birth
Vaginal birth
Emergency caesarian
#
#
No severe PE
Severe PE
pSevereDiseasePreecl
pICU
pNCC_ICU
pNCC_HDU
pNCCnormal
pNCC_ICUPreecl
pNCC_HDUPreecl
pNCCnormalPreecl
ICU admission
HDU admission
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#
#
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Maternal death
Neonatal death
Neonatal survival
Neonatal survival
Neonatal death
pNeonatalDeath_TP
pNeonatalDeath_TP
Maternal survival #
#
#
#
No admission
NCC ICU
NCC HDU
NCC normal care
No admission
NCC ICU
NCC HDU
NCC normal care
FIGURE 12 Structure of therapeutic pathway in the decision-analytic model.
H
EA
LTH
ECO
N
O
M
ICS
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
48
TABLE 66 Transition probabilities used in the model
Transition Value Range Source
Clinician diagnosis
Probability of severe PE 0.2013 0.1765–0.2272 Clinical study
Diagnostic accuracy
Local laboratory – SPCR
Sensitivity 0.8549 0.8020–0.9009 Clinical study
Specificity 0.4021 0.3676–0.4370 Clinical study
Dipstick only
Sensitivity 0.9223 0.8807–0.9556 Clinical study
Specificity 0.1332 0.1100–0.1581 Clinical study
Central laboratorya – SPCR via the BZC assay
Sensitivity 0.8394 0.7845–0.8876 Clinical study
Specificity 0.4321 0.3972–0.4673 Clinical study
Central laboratorya – SPCR via the PGR assay
Sensitivity 0.8549 0.8020–0.9009 Clinical study
Specificity 0.3864 0.3523–0.4212 Clinical study
Central laboratorya – SACR
Sensitivity 0.9689 0.9403–0.9884 Clinical study
Specificity 0.1606 0.1354–0.1874 Clinical study
Central laboratorya – 24-hour urine protein measured via the BZC assay
Sensitivity 0.8342 0.7787–0.8831 Clinical study
Specificity 0.4413 0.4063–0.4765 Clinical study
continued
TABLE 65 Summary of results from statistical analysis
Comparator
Women included
in analysis, n Cases Non-cases TP FP TN FN Sensitivity Specificity
Local laboratory – SPCR 959 193 766 165 458 308 28 0.8549 0.4021
Central laboratorya – SPCR
via the BZC assay
959 193 766 162 435 331 31 0.8394 0.4321
Central laboratorya – SPCR
via the PGR assay
959 193 766 165 470 296 28 0.8549 0.3864
Central laboratorya – SACR 959 193 766 187 643 123 6 0.9689 0.1606
Central laboratorya – 24-hour
urine protein measured using
the BZC assay
959 193 766 161 428 338 32 0.8342 0.4413
Central laboratorya – 24-hour
urine protein measured using
the PGR assay
959 193 766 162 466 300 31 0.8394 0.3916
Dipstick test alone 959 193 766 178 664 102 15 0.9223 0.1332
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a Central laboratory (Kent).
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TABLE 66 Transition probabilities used in the model (continued )
Transition Value Range Source
Central laboratorya – 24-hour urine protein measured via the PGR assay
Sensitivity 0.8394 0.7845–0.8876 Clinical study
Specificity 0.3916 0.3574–0.4264 Clinical study
Type of onset
TP and FN
Spontaneous onset 0 Not reported NICE CG107, table J.11
Induction onset 0.95 Not reported NICE CG107, table J.11
Planned caesarean 0.05 N/A NICE CG107, table J.11
FP and TN
Spontaneous onset 0.027 0.013–0.045 NICE CG107, table I.1a1
Induction onset 0.97 0.952–0.985 NICE CG107, table I.1a1
Planned caesarean 0.003 N/A NICE CG107, table I.1a1
Type of birth
TN/FP, spontaneous/induction onset
Vaginal birth 0.727 0.678–0.768 NICE CG107, table I.1a1
Assisted birth 0.133 0.1–0.169 NICE CG107, table I.1a1
Emergency caesarean 0.14 N/A NICE CG107, table I.1a1
TP, spontaneous/induction onset
Vaginal birth 0.75 Not reported NICE CG107, table J.11
Assisted birth 0.15 Not reported NICE CG107, table J.11
Emergency caesarean 0.10 N/A NICE CG107, table J.11
FN, spontaneous/induction onset
Vaginal birth 0.05 Not reported NICE CG107, table K.41
Assisted birth 0.05 Not reported NICE CG107, table K.41
Emergency caesarean 0.90 Not reported NICE CG107, table K.41
Maternal admission
TN/FP, vaginal/assisted/emergency or planned caesarean
Severe PE 0 N/A Assumption
No severe PE 1 N/A Assumption
TP/FN, vaginal/assisted/emergency or planned caesarean
Severe PE 1 N/A Assumption
No severe PE 0 N/A Assumption
TP/FP/TN, severe PE
HDU 0.99 N/A NICE CG107, table I.1a1
ICU 0.01 0.003–0.023 NICE CG107, table I.1a1
FN, severe PE
HDU 0.95 N/A NICE CG107, table K.41
ICU 0.05 Not reported NICE CG107, table K.41
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Resource use and cost
Resource use assumptions used in the model were derived from multiple sources:
1. Intervention cost for each comparator test were communicated by the study laboratory.
2. Resource use assumptions for the mother and baby in the relevant prenatal and postnatal period were
derived from the models used in NICE’s CG107.1
3. Assumptions regarding length of stay (LOS) in maternal and neonatal intensive care were obtained from
data collected from patients in the clinical study.
Intervention cost
The cost of delivering each test was obtained from the laboratory used to conduct the primary analysis in
the clinical study. Unit costs for each test are summarised in Table 67.
TABLE 66 Transition probabilities used in the model (continued )
Transition Value Range Source
Neonatal admission
TP/FN, HDU/ICU
Neonatal special care 0.4286 N/A NICE CG107, table J.11
Neonatal HDU 0.2857 0.138–0.463 NICE CG107, table J.11
NICU 0.2857 0.138–0.463 NICE CG107, table J.11
No neonatal admission 0 N/A Assumption
FP/TN, HDU/ICU/no severe PE
NSC 0.18 0.143–0.221 NICE CG107, table I.1a1
NHDU 0.03 0.017–0.052 NICE CG107, table I.1a1
NICU 0.03 0.013–0.045 NICE CG107, table I.1a1
No neonatal admission 0.76 N/A NICE CG107, table I.1a1
Mortality
Probability of maternal death
TP 0.0079 Not reported NICE CG107, table K.51
FN 0.009 Not reported NICE CG107, table K.51
TN and FP 0 N/A Assumption
Probability of neonatal death
TP 0.0056 0.00015–0.02224 NICE CG107, table
K.5,1 the confidential
enquiry into maternal
and child health25
FN 0.056 0.036–0.083 NICE CG107, table K.5,1
Douglas and Redman26
TN and FP 0 N/A Assumption
FN, false negative; FP, false positive; N/A, not applicable; TN, true negative; TP, true positive.
a Central laboratory (Kent).
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Treatment cost
Resource-use assumptions from NICE model The analysis incorporated the impact of each strategy on
the use of NHS services by the mother and baby during the neonatal and postnatal period. This included
time spent in the maternal ward, ICU and HDU by the mother and neonatal ICU and HDU by the baby.
The analysis took into account different intensity of care involved in a normal birth, assisted delivery,
and planned and emergency caesarean. In addition, the analysis included the use of medications such as
oxytocin and magnesium sulphate during delivery and labetalol in PE and hypertension in pregnancy.
Resource use assumptions in each pathway were derived from an existing model of care for hypertension
without proteinuria and PE developed by NICE.1
Length of stay in hospital based on collected data The resource use assumptions from the NICE model1
were combined with information prospectively collected for the study participants. This included the following:
1. admissions to the hospital for labour and/or complications
2. admissions to neonatal intensive care, HDUs and special baby units.
Estimates of LOS derived from prospectively collected data are summarised in Table 68.
TABLE 67 Unit costs of laboratory tests
Assay Unit cost (£)
Local laboratory – SPCR 0.70
Central laboratorya – SPCR via the BZC assay 0.70
Central laboratorya – SPCR via the PGR assay 0.70
Central laboratorya – SACR 2.71
Central laboratorya – 24-hour urine protein measured via the BZC assay 1.19
Central laboratorya – 24-hour urine protein measured via the PGR assay 1.19
Dipstick test only 0.00
a Central laboratory (Kent).
TABLE 68 Length of stay in maternal and neonatal units
Type of care Variable name
Number of
observations
Mean LOS, days
(standard error) Description
HDU OUT1_Days_HDU,
OUT1_Days_HDUobstetric
95 2.33 (0.19) Calculated in a subset with
diagnosed severe PE
ICU OUT1_Days_ITU 5 2.20 (0.73) Calculated in a subset with
diagnosed severe PE
Maternal unit OUT2_Tot_PNdays_inpatient 765 3.21 (0.08) Calculated in a subset with
no severe PE diagnosis
Neonatal special care OUT3_1_days_SCBU,
OUT3_1_days_Ventilated
PE: 64;
no PE: 95
PE: 18.55 (1.55);
no PE: 12.78 (1.27)
Calculated separately for
subsets with and with no
severe PE diagnosis
Neonatal HDU and ICU OUT3_1_days_SCBU,
OUT3_1_days_Ventilated
PE: 64;
no PE: 28
PE: 8.27 (1.81);
no PE: 5.14 (1.77)
Calculated separately for
subsets with and with no
severe PE diagnosis
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Data collected alongside the clinical study included the number of inpatient days spent in different hospital
units, which included HDU, ICU, regular postnatal hospital admission for the mother and time spent in
special care baby unit (SCBU) for the baby. Table 68 summarises the data obtained on hospital stays; the
column entitled ‘Variable name’ contains the name of the variable, which was used in the LOS calculation.
The column entitled ‘Description’ outlines the subset of the population that was used to calculate the LOS
estimate. Different subsets defined within the data were used: patients with a clinician diagnosis of severe
PE were used to determine the mean LOS in maternal HDU and ICU. Mean LOS in neonatal units was
estimated separately in patients with and without severe PE, as the presence of severe disease may have
affected the intensity and cost of neonatal care.
It was assumed that neonates who required ventilation were admitted to neonatal HDU or ICU and the length
of time in ventilation (reported in variable OUT3_1_days_Ventilated) was assumed to be the LOS in HDU or
ICU. The data set did not make a distinction between neonatal HDU and ICU. The mean LOS was assumed to
the same in neonatal HDU and ICU, which is consistent with the assumptions made in the NICE hypertension
in pregnancy economic model.1 The LOS in neonatal special care was estimated as the time spent in ventilation
(HDU/ICU based on above assumption) subtracted from the total time spent in SCBU. The excess LOS in a
regular maternal unit was assumed to be 2 days, which is the same as in the NICE model. Based on data from
the current study, the average LOS was 3.21 days compared with a national average of 1.24 days reported in
NHS Reference Costs 2014/1527 for Healthcare Resource Group (HRG) NZ30C.
Unit costs
Unit costs were derived from up-to-date routine sources, such as the NHS Reference Costs 2014/15 for
secondary care27 and the British National Formulary for medications.28 A list of cost items used in the model
are included in Table 69.
Summary of state costs
A summary of state costs (resource use assumptions combined with unit costs) are summarised in Table 69.
Outcomes
Quality-adjusted life-year calculations
The modelling analysis estimated outcomes of treatment in terms of QALYs gained over a lifetime horizon
in both the mother and baby. It employed the same assumptions regarding QALY generation in
hypertension without proteinuria and PE as the NICE models included in NICE’s CG107,1 as described in
Model structure. The following assumptions were made, which were tested in the sensitivity analyses:
l The time interval of the impact of PE is brief, with surviving mothers returning to full health following
treatment. Therefore, this short period was not assumed to impact on the number of QALYs generated
in the different arms of the model.
l Severe PE was assumed to impact on the mean QALYs gained over a lifetime through increased
maternal and neonatal mortality. This information was derived from the confidential enquiry into
maternal and child health25 and Douglas and Redman.26
l A neonatal death was assumed to be a loss of 27.7 discounted (3.5% per annum) QALYs, based on
calculations in the NICE hypertension in pregnancy model which assumed a life expectancy of 80 years.
l A maternal death was assumed to be a loss of 24.8 discounted QALYs, based on mean age at birth of
29 years and a remaining life expectancy of 53 years.
Analysis methods
Descriptive statistics
The mean cost and QALY gained per patient were presented using arithmetic means. In probabilistic
analyses, comparisons of costs, QALYs and incremental cost-effectiveness ratios (ICERs) across alternative
strategies were made using arithmetic means and 95% CIs of the mean computed using standard errors.
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TABLE 69 Summary of cost items used in the model
Category
Episode
cost (£) Range (£) Details
Source of
resource use
assumption
Source of
unit cost
Laboratory tests
Local laboratory – SPCR 0.70 – – Study
laboratory
Personal
communicationa
Central laboratoryb – SPCR
via the BZC assay
0.70 – – Study
laboratory
Personal
communicationa
Central laboratoryb – SPCR
via the PGR assay
0.70 – – Study
laboratory
Personal
communicationa
Central laboratoryb – SACR 2.71 – – Study
laboratory
Personal
communicationa
Central laboratoryb –
24-hour urine protein
using the BZC assay
1.19 – – Study
laboratory
Personal
communicationa
Central laboratoryb –
24-hour urine protein
using the PGR assay
1.19 – – Study
laboratory
Personal
communicationa
Type of delivery
Unassisted 1513.06 693.36–1790.25 HRG NZ30C Update of
NICE model
NHS Reference
Costs 2014/1527
Assisted 1887.17 1469.65–1887.17 HRG NZ31C Update of
NICE model
NHS Reference
Costs 2014/1527
Planned caesarean 3106.32 2516.77–3506.77 HRG NZ50C Update of
NICE model
NHS Reference
Costs 2014/1527
Emergency caesarean 3894.84 3095.07–4699.48 HRG NZ51C Update of
NICE model
NHS Reference
Costs 2014/1527
Hospital admission
Maternal ward 820.56 329.56–861.68 HRG NZ30C, based
on a LOS of 2 days
Update of
NICE model
NHS Reference
Costs 2014/1527
Maternal ward excess day 410.28 164.78–430.84 HRG NZ30C Update of
NICE model
NHS Reference
Costs 2014/1527
HDU 1973.43 1669.78–2364.82 HRG XC04Z, based
on a LOS of 2 days
Update of
NICE model
NHS Reference
Costs 2014/1527
ICU 3145.34 2664.34–3581.30 HRG XC06Z, based
on a LOS of 2 days
Update of
NICE model
NHS Reference
Costs 2014/1527
Neonatal care
Neonatal special care 1598.85 1292.37–1913.31 HRG XA03Z, based
on a LOS of 3 days
Update of
NICE model
NHS Reference
Costs 2014/1527
Neonatal special care in PE 2611.46 2110.87–3125.07 HRG XA03Z, based
on a LOS 4.9 days
Update of
NICE model
NHS Reference
Costs 2014/1527
Neonatal HDU 2541.04 2128.59–2921.01 HRG XA01Z, based
on a LOS of 3 days
Update of
NICE model
NHS Reference
Costs 2014/1527
Neonatal HDU in PE 4151.04 3476.70–4770.98 HRG XA01Z, based
on a LOS of 4.9 days
Update of
NICE model
NHS Reference
Costs 2014/1527
Neonatal ICU 3529.41 2620.53–4223.67 HRG XA02Z, based
on a LOS of 3 days
Update of
NICE model
NHS Reference
Costs 2014/1527
Neonatal ICU in PE 5764.70 4280.20–6898.66 HRG XA02Z, based
on a LOS of 4.9 days
Update of
NICE model
NHS Reference
Costs 2014/1527
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Base-case cost-effectiveness analysis
Cost-effectiveness of each test was presented using ICERs, which estimate incremental cost per unit of
outcome gained over a baseline comparator. This was done using pairwise comparisons of each test
compared with the baseline comparator (the local laboratory’s SPCR test). The ICER was explicitly examined
only if it was positive (either both cost and outcome is higher, or both are lower compared with standard
care). In the case of a negative ICER, the corresponding comparator was defined as either dominant
(in case of incremental QALY gain) or dominated (in case of incremental QALY loss).
Deterministic sensitivity analysis
The robustness of the results of the cost-effectiveness analysis was examined in one-way sensitivity
analyses by changing the assumed values of model inputs. Defensible ranges for model parameters were
obtained from clinical experts and literature. The following model parameters will be tested.
Transition probabilities
1. Probability of severe PE.
2. Sensitivity and specificity of each test.
3. Probability of different modes of induction (spontaneous, induced, caesarean section) in hypertension
without proteinuria and PE.
4. Probability of different types of birth (normal, assisted, emergency caesarean).
5. Probability of admission to maternal HDU/ICU in PE.
6. Probability of neonatal admission to HDU/ICU.
7. Maternal and neonatal mortality in severe PE.
Resource use and cost
1. LOS (days) in maternal/neonatal HDU/ICU.
2. Unit costs of hospital admission to maternal ward/HDU/ICU.
3. Unit costs of hospital admission to NICU/SCBU/HDU/ICU.
4. Unit costs of different types of delivery.
TABLE 69 Summary of cost items used in the model (continued )
Category
Episode
cost (£) Range (£) Details
Source of
resource use
assumption
Source of
unit cost
Medications
Dinoprostone 26.56 – Two doses of 3-mg
tablets
Update of
NICE model
BNF28
Dexamethasone 74.88 – Four intramuscular
doses of 12 mg
Update of
NICE model
BNF28
Labetalol 7.37 – Intravenous Update of
NICE model
BNF28
Magnesium sulphate 38.55 – One dose of
4 mg+ 24 intravenous
doses of 2 mg
Update of
NICE model
BNF28
Oxytocin 15.50 – 5 ml of oxytocin,
staff cost (£20) and
disposables (£7), used
in 40% of cases
Update of
NICE model
BNF28
BNF, British National Formulary.
a Dr Edmund Lamb, Consultant Clinical Scientist, East Kent Hospitals University Foundation Trust 2016, personal
communication.
b Central laboratory (Kent).
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Probabilistic sensitivity analysis
A probabilistic sensitivity analysis (PSA) was conducted in order to examine the combined uncertainty of all
parameters used in the model on the model results. Distributional assumptions were made in case of each
model parameter based on their expected value and CI derived from literature or expert opinion (distribution
parameters are listed in Table 70). Cost parameters and lifetime QALY gains were assumed to approximate a
gamma distribution as they are strictly non-negative, contain a large proportion of zero values (non-users for
cost estimates and patients who have died for QALY estimates) and a positive skew because of outliers. Beta
distribution was assumed for transition probabilities which are bounded between 0 and 1. Parameter values
were repeatedly sampled over 5000 iterations in order to construct a 95% CI for the ICER. The results of
each iteration were mapped on an incremental cost-effectiveness plane to illustrate the uncertainty in the
ICER estimate. Decision uncertainty was illustrated using a cost-effectiveness acceptability curve to map
the probability of cost-effectiveness of each comparator over a range of ceiling willingness-to-pay (WTP)
values per QALY gain by NICE (£0–100,000).
TABLE 70 Ranges and distribution parameters used in the deterministic sensitivity analysis and PSA
Parameter
Analysis
Source
Deterministic sensitivity PSA
Minimum
value
Maximum
value
Distribution
type
Distribution
parameters
Probability of severe PE 0.1765 0.2272 Beta α = 193,
β = 766
95% CI of beta distribution
Local laboratory
SPCR test
Sensitivity 0.8020 0.9009 Beta α = 165,
β = 28
95% CI of beta distribution
Specificity 0.3676 0.4370 α = 308,
β = 458
Dipstick test only
Sensitivity 0.8807 0.9556 Beta α = 178,
β = 15
95% CI of beta distribution
Specificity 0.1100 0.1581 α = 102,
β = 664
Central laboratory
SPCR test
BZC assay
Sensitivity 0.7845 0.8876 Beta α = 162,
β = 31
95% CI of beta distribution
Specificity 0.3972 0.4673 α = 331,
β = 435
PGR assay
Sensitivity 0.8020 0.9009 Beta α = 165,
β = 28
95% CI of beta distribution
Specificity 0.3523 0.4212 α = 296,
β = 470
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TABLE 70 Ranges and distribution parameters used in the deterministic sensitivity analysis and PSA (continued )
Parameter
Analysis
Source
Deterministic sensitivity PSA
Minimum
value
Maximum
value
Distribution
type
Distribution
parameters
SACR test
Sensitivity 0.9403 0.9884 Beta α = 643,
β = 6
95% CI of beta distribution
Specificity 0.1354 0.1874 α = 123,
β = 664
24-hour urine test
BZC assay
Sensitivity 0.7787 0.8831 Beta α = 161,
β = 32
95% CI of beta distribution
Specificity 0.4063 0.4765 α = 338,
β = 428
PGR assay
Sensitivity 0.7845 0.8876 Beta α = 162,
β = 31
95% CI of beta distribution
Specificity 0.3574 0.4264 α = 300,
β = 466
FP and TN
Spontaneous onset 0.013 0.045 α = 10,
β = 367
NICE’s CG107 (appendices I and J)1
Induction onset 0.952 0.985 α = 366,
β = 11
TN/FP
Spontaneous/induction onset
Vaginal birth 0.678 0.768 α = 273,
β = 104
NICE’s CG107 (appendices I and J)1
Assisted birth 0.100 0.169 α = 50,
β = 327
TP/FP/TN
Severe PE
ICU 0.003 0.023 α = 4,
β = 373
NICE’s CG107 (appendices I and J)1
TP/FN
HDU/ICU
NHDU 0.138 0.463 α = 8, β = 20 NICE’s CG107 (appendices I and J)1
NICU 0.138 0.463 α = 8, β = 20
continued
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TABLE 70 Ranges and distribution parameters used in the deterministic sensitivity analysis and PSA (continued )
Parameter
Analysis
Source
Deterministic sensitivity PSA
Minimum
value
Maximum
value
Distribution
type
Distribution
parameters
FP/TN
HDU/ICU/no severe PE
NSC 0.143 0.221 α = 68,
β = 309
NICE’s CG107 (appendices I and J)1
NHDU 0.017 0.052 α = 12,
β = 365
NICU 0.013 0.045 α = 10,
β = 367
Probability of maternal death
TP 0.00395 0.01185 Beta Not reported Not reported in NICE report1
assumed range 50–150% of
base caseFN 0.0045 0.0135 Not reported
TP 0.00015 0.02224 α = 1,
β = 164
The confidential enquiry into
maternal and child health25
FN 0.036 0.083 α = 22,
β = 361
Douglas and Redman26
Maternal
Unit 1.816 2.130 Gamma κ = 606.39,
θ = 0.0032
95% CI from study data
HDU 1.972 2.717 κ = 150.39,
θ = 0.0155
ICU 1.010 3.845 κ = 9.082,
θ = 0.242
Neonatal
Special care
No PE 10.412 15.387 Gamma κ = 101.264,
θ = 0.126
95% CI from study data
PE 15.637 21.709 κ = 143.227,
θ = 0.1295
HDU/ICU
No PE 2.278 9.146 Gamma κ = 8.433,
θ = 0.61
95% CI from study data
PE 5.111 12.177 κ = 20.876,
θ = 0.396
Delivery
Normal 693.36 1790.25 Gamma κ = 24.68,
θ = 61.31
25th and 75th percentile from
NHS Reference Costs 2014/1527
Assisted 1469.65 1887.17 κ = 499.11,
θ = 3.781
HEALTH ECONOMICS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
58
Results
Base-case analysis
The mean cost and QALYs of each strategy are summarised in Table 71. The central laboratory’s SACR test
was the most effective strategy, generating 52.42 QALYs. The least costly strategy was 24-hour urine
collection using the BZC assay (£6615.46), which was £72 lower than the most costly strategy, dipstick
only (£6687.35).
TABLE 70 Ranges and distribution parameters used in the deterministic sensitivity analysis and PSA (continued )
Parameter
Analysis
Source
Deterministic sensitivity PSA
Minimum
value
Maximum
value
Distribution
type
Distribution
parameters
Caesarean
Planned 2516.77 3506.32 Gamma κ= 150.88,
θ = 20.59
25th and 75th percentile from
NHS Reference Costs 2014/1527
Emergency 3095.07 4699.48 κ= 90.36,
θ = 43.1
Maternal
Ward 164.78 430.84 Gamma κ= 32.65,
θ = 12.565
25th and 75th percentile from
NHS Reference Costs 2014/1527
HDU 834.89 1182.41 κ= 123.67,
θ = 7.98
ICU 1332.17 1790.65 κ= 180.89,
θ = 8.71
Neonatal
ICU 873.51 1407.89 Gamma κ= 74.14,
θ = 15.87
25th and 75th percentile from
NHS Reference Costs 2014/1527
HDU 709.53 973.67 κ= 157.84,
θ = 5.37
Special care 430.79 637.77 κ= 101.69,
θ = 5.24
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
TABLE 71 Mean cost and QALYs of each strategy
Strategy Mean cost (£) Mean QALY gain
Local laboratory – SPCR 6621.27 52.39
Central laboratorya – SACR 6666.34 52.42
Dipstick test only 6687.35 52.41
Central laboratorya – SPCR via the PGR assay 6626.41 52.39
Central laboratorya – 24-hour urine protein
measured via the BZC assay
6615.46 52.38
Central laboratorya – SPCR via the BZC assay 6616.34 52.38
Central laboratorya – 24-hour urine protein
measured via the PGR assay
6630.11 52.38
a Central laboratory (Kent).
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A cost-effectiveness frontier was constructed to determine which options are dominated (Figure 13).
The 24-hour urine test (PGR assay), central laboratory’s SPCR test (PGR assay) and dipstick test only were
absolutely dominated as there was at least one other strategy which was both more effective and less
costly. Non-dominated strategies positioned along the cost-effectiveness frontier were 24-hour urine test
(BZC assay), central laboratory’s SPCR test (BZC assay), local laboratory’s SPCR test and central laboratory’s
SACR test.
Analysis of incremental cost-effectiveness
The incremental cost-effectiveness of each option compared with the local laboratory’s SPCR test
(the baseline comparator) is represented in Table 72. ICERs were calculated according to the methods
outlined in Analysis methods. The effectiveness of all seven comparators was very similar: the difference
between the least and most effective strategy was 0.04 QALYs, which corresponds to 14.6 days in full
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24-hour urine BZC
24-hour urine PGR
Central laboratory SACR
Central laboratory SPCR BZC
Central laboratory SPCR PGR
Dipstick only
Local laboratory SPCR
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Undominated
FIGURE 13 Mean cost and QALYs of each strategy.
TABLE 72 Incremental cost-effectiveness of each option
Strategy
Incremental cost (£) vs. local
laboratory SPCR test
Incremental QALYs vs. local
laboratory SPCR test
ICER
(£/QALY)
Central laboratorya – SACR 45.07 0.03 1502
Dipstick test only 66.08 0.02 3304
Central laboratorya – SPCR via the
PGR assay
5.14 0 Dominated
Central laboratorya – 24-hour urine
protein measured via the BZC assay
–5.81 –0.01 581
Central laboratorya – SPCR via the
BZC assay
–4.93 –0.01 493
Central laboratorya – 24-hour urine
protein measured via the PGR assay
8.84 –0.01 Dominated
a Central laboratory (Kent).
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health. Differences in mean cost were more substantial: the most costly strategy (dipstick only) was £66
higher than the local laboratory’s SPCR test. The least costly (24-hour urine test using the BZC assay)
was £6 lower than the baseline comparator. Two strategies were dominated compared with the baseline
comparator: the central laboratory’s SPCR test, which was equally effective and more costly, and the
24-hour urine collection using the PGR assay, which was both more costly and less effective.
Deterministic sensitivity analysis
The differences in cost and QALYs generated across strategies were small, meaning that small changes in
the values of input parameters could impact on the cost-effectiveness ranking of the comparators. To
identify the main sources of uncertainty in the model, tornado diagrams (Figure 14) were constructed to
assess the effect of varying model inputs on the net monetary benefit (NMB) assuming a WTP of £20,000
per QALY.
Diagnostic accuracy parameters
The probability of severe PE and sensitivity of the central laboratory’s SACR test were the largest sources of
uncertainty. However, varying the values of these parameters over their pre-assigned range did not result
in a change of optimal strategy, as shown in the one-way sensitivity analysis in Figure 15 and the tornado
analysis in Figure 16.
Transition probabilities in the treatment pathway
The most significant source of uncertainty was the probability of neonatal special care admission in
patients with no PE. This was investigated in a one-way sensitivity analysis in Figure 17 and tornado
analysis in Figure 18. Changing the probability did not affect the cost-effectiveness ranking.
1,041,200 1,041,600
NMB (£)
1,042,000
EV: 1,041,742.16
Probability of severe PE (0.1765 to 0.2272)
Central laboratory – SACR sensitivity 
(0.9403 to 0.9884)
Central laboratory – SACR specificity 
(0.1354 to 0.1874)
1,042,400
FIGURE 14 Diagnostic accuracy parameters. EV, expected value.
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Probability of severe PE
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FIGURE 15 Marginal effect of varying probability in severe PE.
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Neonatal ICU non-PE (0.013 to 0.045)
Normal birth (0.678 to 0.768)
Neonatal HDU non-PE (0.017 to 0.052)
Assisted birth (0.1 to 0.169)
Spontaneous onset (0.013 to 0.0299)
Induced onset (0.952 to 0.97)
Maternal ICU (0.003 to 0.023)
FIGURE 16 Tornado analysis, pathway probabilites. EV, expected value.
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Probability of death
The probability of neonatal death in true positives was the largest source of uncertainty. This was explored
in a one-way sensitivity analysis in Figure 19 and tornado analysis in Figure 20. Varying the value of the
parameter did not affect the cost-effectiveness ranking.
Length of stay in maternal and neonatal units
Length of stay in neonatal HDU and ICU in patients with PE was the largest source of uncertainty. This was
explored in a one-way sensitivity analysis in Figure 21 and the tornado analysis in Figure 22. There was no
effect on the ranking of comparators.
Probability of neonatal SC admission
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FIGURE 17 Marginal effect of varying the probability of neonatal SCBU admission.
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Neonatal death FN (0.036 to 0.083)
Maternal death FN (0.0045 to 0.0135)
FIGURE 18 Tornado analysis, probability of death. EV, expected value.
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Probability of death, true positive
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FIGURE 19 Marginal effect of changing the probability of neonatal death in true positives.
1,041,200
EV: – 6615.4648415798565
1,041,400 1,041,600 1,041,800 1,042,000 1,042,200
NMB (£)
Neonatal HDU/ICU LOS PE 
(5.111 to 12.177)
Neonatal SC LOS non-PE 
(10.412 to 15.387)
Neonatal HDU/ICU LOS non-PE 
(2.278 to 9.14)
Neonatal SC LOS PE 
(15.637 to 21.709)
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FIGURE 20 Tornado analysis, LOS. EV, expected value.
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LOS in neonatal HDU/ICU
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FIGURE 21 Marginal effect or neonatal HDU/ICU LOS.
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(430.79 to 637.77)
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Neonatal ICU per day
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FIGURE 22 Tornado analysis (NMB) unit costs. EV, expected value.
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Unit costs
The largest contributors to uncertainty in cost parameters were neonatal SCBU and maternal ward daily
costs. These were explored in one-way analyses represented in Figures 23 and 24. There was no effect on
cost-effectiveness rankings.
Cost per day in neonatal SC (£)
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FIGURE 23 Marginal effect of cost of neonatal special care.
Cost per day in maternal ward (£)
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FIGURE 24 Marginal effect of cost in maternal ward.
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Probabilistic sensitivity analysis
Summary of probabilistic sensitivity analysis results
Tables 73 and 74 demonstrate the mean and incremental values of cost, QALYs gained and ICER for each
comparator test based on the PSA with 95% CIs. The differences in cost and QALYs were small, resulting
in wide CIs for the ICER estimates. The most cost-effective test was the central laboratory’s SACR test,
which had an ICER of £1255 compared with the local laboratory’s SPCR test, although the 95% CI crossed
zero (–£6124 to £8635). Despite the wide range, the upper bound of the CI was below the NICE threshold
for acceptability of new health-care technology of £20,000 per QALY gained.
TABLE 73 Mean cost and QALYs of each strategy
Strategy
Mean (95% CI)
Cost (£) QALY gain
Local laboratory SPCR test 6504.11 (5682.16 to 7326.06) 52.38 (52.32 to 52.44)
Central laboratorya – SACR 6544.25 (5716.62 to 7371.88) 52.42 (52.36 to 52.48)
Dipstick test only 6570.77 (5740.36 to 7401.18) 52.40 (52.34 to 52.46)
Central laboratorya – SPCR via the PGR assay 6509.36 (5686.14 to 7332.58) 52.38 (52.32 to 52.44)
Central laboratorya – 24-hour urine protein
measured via the BZC assay
6498.29 (5677.05 to 7319.53) 52.38 (52.32 to 52.44)
Central laboratorya – SPCR via the BZC assay 6499.11 (5678.07 to 7320.15) 52.38 (52.32 to 52.44)
Central laboratorya – 24-hour urine protein
measured via the PGR assay
6513.01 (5689.95 to 7336.07) 52.38 (52.32 to 52.44)
a Central laboratory (Kent).
TABLE 74 Incremental cost-effectiveness of each option
Strategy
Incremental cost (£)
vs. local laboratory
SPCR test (95% CI)
Incremental QALYs vs.
local laboratory SPCR
test (95% CI) ICER (£/QALY) (95% CI)
Central laboratorya – SACR 40.14 (0.39 to 79.89) 0.04 (0.02 to 0.06) 1255.27
(–6124.03 to 8634.57)
Dipstick test only 66.66 (26.19 to 107.13) 0.02 (0 to 0.04) 5077.07
(–87,873.40 to 98,027.50)
Central laboratorya – SPCR
via the PGR assay
5.26 (–22.77 to 33.29) 0 (–0.02 to 0.02) Dominated
(–73,092.20 to 71,792.53)
Central laboratorya –
24-hour urine protein
measured via the BZC assay
–5.82 (–34.79 to 23.15) –0.01 (–0.03 to 0.01) Dominated
(–84,381.80 to 83,366.32)
Central laboratorya – SPCR
via the BZC assay
–5.00 (–33.60 to 23.60) –0.01 (–0.03 to 0.01) 674.44
(–119,920.09 to 121,268.97)
Central laboratorya –
24-hour urine protein
measured via the PGR assay
8.91 (–19.43 to 37.25) –0.01 (–0.03 to 0.01) Dominated
(–162,414.22 to 157,255.86)
a Central laboratory (Kent).
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Because the CI for the ICER crossed zero in every comparison, 2 × 2 tables representing the distribution of
the ICER estimates in the PSA across the four quadrants of the cost-effectiveness plane (Tables 75–80)
were used in combination with graphical representation of the PSA output using cost-effectiveness planes
(Figures 25–30) to interpret the uncertainty around the ICER estimate. The ICER of central laboratory SACR
test is distributed across the north-east (97.7% of points) and south-east (2.3%) quadrants, meaning that
the negative range of the ICER represents cost savings, which supports the argument that the central
laboratory’s SACR test was likely to be cost-effective compared with the local laboratory’s SPCR test. The
dipstick-only strategy was the second most likely to be cost-effective, with 98.4% of points representing
higher cost and higher outcome, although it was dominated in 1.5% of cases. The other four strategies
(central laboratory’s SPCR test and the 24-hour urine test for both the PGR and BZC assays) had a
significant probability of being either dominant or dominated, which is explained by small differences and
significant uncertainty in cost and outcome per patient.
Incremental cost-effectiveness planes
Figures 25–30 represent incremental cost-effectiveness planes for each test versus the baseline comparator
(the local laboratory’s SPCR test), which plot each combination of incremental cost and effect generated
in the PSA. A line representing the standard ceiling WTP per QALY recommended by NICE is overlaid
for reference.
TABLE 75 The central laboratory’s SACR test vs. the local laboratory’s SPCR test
Negative incremental effect (%) Positive incremental outcome (%)
Positive incremental cost (%) 0 97.7
Negative incremental outcome (%) 0 2.3
TABLE 76 The dipstick test only vs. the local laboratory’s SPCR test
Negative incremental effect (%) Positive incremental outcome (%)
Positive incremental cost (%) 1.5 98.4
Negative incremental outcome (%) 0 0.1
TABLE 77 The central laboratory’s SPCR test (measured via the PGR assay) vs. the local laboratory’s SPCR test
Negative incremental effect (%) Positive incremental outcome (%)
Positive incremental cost (%) 45.1 18.4
Negative incremental outcome (%) 4.3 32.2
TABLE 78 The 24-hour urine test (measured via the BZC assay) vs. the local laboratory’s SPCR test
Negative incremental effect (%) Positive incremental outcome (%)
Positive incremental cost (%) 33.6 0.6
Negative incremental outcome (%) 39.1 26.6
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FIGURE 25 Incremental cost-effectiveness plane: the central laboratory’s SACR test vs. the local laboratory’s SPCR
test. The line represents the standard ceiling WTP per QALY recommended by NICE.
TABLE 79 The central laboratory’s SPCR test (measured via the BZC assay) vs. the local laboratory’s SPCR test
Negative incremental effect (%) Positive incremental outcome (%)
Positive incremental cost (%) 34.9 1.3
Negative incremental outcome (%) 32.0 31.9
TABLE 80 The 24-hour urine test (measured via the PGR assay) vs. the local laboratory’s SPCR test
Negative incremental effect (%) Positive incremental outcome (%)
Positive incremental cost (%) 60.6 12.8
Negative incremental outcome (%) 5.7 20.9
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FIGURE 26 Incremental cost-effectiveness plane: dipstick test only vs. the local laboratory’s SPCR test. The line
represents the standard ceiling WTP per QALY recommended by NICE.
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FIGURE 27 Incremental cost-effectiveness plane: the central laboratory’s SPCR test (measured via the PGR assay) vs.
the local laboratory’s SPCR test. The line represents the standard ceiling WTP per QALY recommended by NICE.
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FIGURE 28 Incremental cost-effectiveness plane: the 24-hour urine test (measured via the BZC assay) vs. the local
laboratory’s SPCR test. The line represents the standard ceiling WTP per QALY recommended by NICE.
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Cost-effectiveness acceptability curve
Figure 31 plots the probability of cost-effectiveness of each comparator against ceiling WTP levels ranging
from £0 to £30,000 per QALY. The central laboratory’s SACR test was deemed to have a 100% probability
of being the most cost-effective option at the standard WTP threshold of £20,000–30,000 per QALY
recommended by NICE.
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FIGURE 29 Incremental cost-effectiveness plane: the central laboratory’s SPCR test (measured via the BZC assay) vs.
the local laboratory’s SPCR test. The line represents the standard ceiling WTP per QALY recommended by NICE.
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FIGURE 30 Incremental cost-effectiveness plane: the 24-hour urine test (measured via the PGR assay) vs. the local
laboratory’s SPCR test. The line represents the standard ceiling WTP per QALY recommended by NICE.
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FIGURE 31 Cost-effectiveness acceptability curve.
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Chapter 5 Discussion and conclusions
Study design, progress and prosecution
This study was designed to explore the challenges of measuring proteinuria in the management of PE and
to determine the most reliable method of measurement for future management algorithms within the UK’s
NHS. We also set out to determine whether or not there was a level of proteinuria that best predicted
(or excluded) severe maternal and perinatal morbidity.
The trial was conducted within the UK and in this clinical setting the management of HDP is heavily
influenced by guidance published by NICE in 20101 (and not due for review until September 2016).
When NICE published in 2010, it reviewed all of the evidence regarding proteinuria measurement and
made several clinical and research recommendations. Its clinical recommendations for the measurement of
proteinuria were:
1.3.1.1 Use an automated reagent-strip reading device or a spot urinary protein : creatinine ratio for
estimating proteinuria in a secondary care setting.
1.3.1.2 If an automated reagent-strip reading device is used to detect proteinuria and a result of 1+
or more is obtained, use a spot urinary protein : creatinine ratio or 24-hour urine collection to quantify
proteinuria.
1.3.1.3 Diagnose significant proteinuria if the urinary protein : creatinine ratio is greater than
30 mg/mmol or a validated 24-hour urine collection result shows greater than 300 mg protein.
1.3.1.4 Where 24-hour urine collection is used to quantify proteinuria, there should be a recognised
method of evaluating completeness of the sample.
National Institute for Health and Clinical Excellence (2010) Hypertension in Pregnancy: The
Management of Hypertensive Disorders during Pregnancy. Available from: www.nice.org.uk/guidance/
cg107.1 NICE guidance is prepared for the National Health Service in England, and is subject to regular
review and may be updated or withdrawn. NICE has not checked the use of its content in this article
to confirm that it accurately reflects the NICE publication from which it is taken. Copyright © 2017
National Institute for Health and Care Excellence. All rights reserved.
Its research recommendations were:
Most adverse outcomes in new-onset hypertensive disorders during pregnancy arise in women
with proteinuria. However, the quality of evidence for the diagnosis of significant proteinuria is
poor and the prognostic value of different quantities of urinary protein is unclear. There is a need
for large, high-quality prospective studies comparing the various methods of measuring proteinuria
(automated reagent-strip reading devices, urinary protein : creatinine ratio, urinary albumin :
creatinine ratio, and 24-hour urine collection) in women with new-onset hypertensive disorders during
pregnancy. The studies should aim to determine which method of measurement, and which diagnostic
thresholds, are most accurate in predicting clinically important outcomes. Such studies would inform
decisions regarding clinical management of new-onset hypertensive disorders during pregnancy.
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If predictive parameters were identified then interventions based on these and aimed at improving
outcomes could be evaluated in randomised clinical trials.
National Institute for Health and Clinical Excellence (2010) Hypertension in Pregnancy: The
Management of Hypertensive Disorders during Pregnancy. Available from: www.nice.org.uk/guidance/
cg107.1 NICE guidance is prepared for the National Health Service in England, and is subject to regular
review and may be updated or withdrawn. NICE has not checked the use of its content in this article
to confirm that it accurately reflects the NICE publication from which it is taken. Copyright © 2017
National Institute for Health and Care Excellence. All rights reserved.
For centres to participate in the trial, compliance with NICE’s CG107 was mandatory, and we utilised
NICE’s definitions of PE and severe PE to create as homogeneous a participant group as possible.
It is accepted that PE is associated with severe maternal and perinatal morbidity and so we wanted to
determine whether or not proteinuria could be used as a meaningful predictor of these more clinically
important end points. For maternal outcomes, we chose the use of the severe PE management algorithm
and magnesium sulphate for eclampsia prophylaxis. This is the treatment pathway that clinicians reserve
for those women who (1) fulfil a definition of severe PE and (2) are of most clinical concern to the team
providing the medical care. We refer to this group as severe PE clinician diagnosis. For perinatal outcomes,
we chose a composite including stillbirth and neonatal death along with the major complications of
preterm delivery that may have long-term health implications to a surviving infant (Table 13).
Our initial calculations of disease prevalence meant that we realistically expected to complete the trial in
three Clinical Research Networks regions and it became clear within months that more centres would be
required to maintain recruitment. This unexpected shortfall was explored through the recruitment logs
from recruiting centres and it was noted that the number of eligible women was below expected and that
many women had a management plan that included an offer of immediate delivery (either induction of
labour or caesarean birth) and, hence, they were not offered participation in this trial, as they would not
have had time to collect a 24-hour urine sample.
The CG107 published by NICE does make recommendations regarding timing of delivery in women who
have hypertension without proteinuria as well as PE. These recommendations are listed below for
gestational hypertension 1.4.2.1–1.4.2.3 and for PE 1.5.2.5–1.5.2.7:
1.4.2.1 Do not offer birth before 37 weeks to women with gestational hypertension whose blood
pressure is lower than 160/110 mmHg, with or without antihypertensive treatment.
1.4.2.2 For women with gestational hypertension whose blood pressure is lower than 160/110 mmHg
after 37 weeks, with or without antihypertensive treatment, timing of birth, and maternal and fetal
indications for birth should be agreed between the woman and the senior obstetrician.
1.4.2.3 Offer birth to women with refractory severe gestational hypertension after a course of
corticosteroids (if required) has been completed.
1.5.2.5 Recommend birth for women who have pre-eclampsia with severe hypertension after
34 weeks when their blood pressure has been controlled and a course of corticosteroids has been
completed (if appropriate).
1.5.2.6 Offer birth to women who have pre-eclampsia with mild or moderate hypertension at 34+0
to 36+6 weeks depending on maternal and fetal condition, risk factors and availability of neonatal
intensive care.
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1.5.2.7 Recommend birth within 24–48 hours for women who have pre-eclampsia with mild or
moderate hypertension after 37+0 weeks.
National Institute for Health and Clinical Excellence (2010) Hypertension in Pregnancy: The
Management of Hypertensive Disorders during Pregnancy. Available from: www.nice.org.uk/guidance/
cg107.1 NICE guidance is prepared for the National Health Service in England, and is subject to regular
review and may be updated or withdrawn. NICE has not checked the use of its content in this article
to confirm that it accurately reflects the NICE publication from which it is taken. Copyright © 2017
National Institute for Health and Care Excellence. All rights reserved.
These recommendations have clearly been widely implemented and resulted in most women with either
gestational hypertension or PE being delivered either at 37 completed weeks of gestation or immediately
on diagnosis if diagnosed after 37 weeks’ gestation.
To our knowledge, this is the first major trial that has captured this change in practice, and there are
significant implications if all women with this diagnosis are delivered before spontaneous labour occurs. It is
not clear, and we are unable to determine, whether the decision to deliver the baby is shared between the
clinician and patient, is recommended by clinicians and women agree or is requested by women and
clinicians agree.
This change in practice highlights the potential benefit of a ‘rule-out’ test that may allow a woman to be
reassured that severe morbidity will not occur, that her pregnancy can, therefore, continue and that
medical intervention may be minimised.
We also noted that as we expanded the trial to recruit in 36 centres that the practice of using a 24-hour
urine collection as part of routine clinical care has dramatically reduced in favour of a SPCR test. As such,
although most centres did still employ the test occasionally, the majority of the 24-hour urine samples
collected for this study was primarily for the trial. Having to collect this additional sample, which was seen
as cumbersome and not part of the unit’s CGs, was the other major reason for women refusing to
participate and recruitment taking longer to complete.
Diagnosis of severe pre-eclampsia
When NICE’s CG107 definition1 of severe PE is assessed it is striking that the prevalence was 44% in the
recruited population and 43% in the population used for the primary analysis (with all completed samples).
This is considerably higher than expected and is in stark contrast to the number of women who had a
clinician diagnosis of severe PE (20%). However, we had expected (at study design) a prevalence of 5%
and, hence, the number needed to be recruited was revised after the interim analysis of outcomes.
This finding has not been reported before in such a large study. Demographically, the population of women
recruited was predominantly low risk with a median age of 30 years, body mass index of 28 kg/m2 and 64%
were nulliparous. There were 53 (6%) multiple pregnancies. In total, 19% had previous hypertension in
pregnancy, which is just over half of the multiparous women recruited, and 22% of the women were
taking aspirin during their pregnancy for PE prevention.
Defining severe PE has always been challenging when the syndrome can be so varied. However, all definitions
include the use of severe hypertension (systolic BP of > 160mmHg and/or diastolic BP of > 110mmHg) as one
key feature of the typical phenotype. In this study, we have noted a very high prevalence of severe hypertension
(88%) and this is likely to account for the very high prevalence of severe PE recorded. We chose to apply
NICE’s definition of severe disease but the prevalence would have been the same if we had used the American
College of Obstetricians and Gynecologists’10 definition or the Society of Obstetric Medicine of Australia and
New Zealand or the Canadian Society’s definitions.9
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We also noted significant perinatal morbidity in the cohort, with 23% of women delivered prior to 36
completed weeks of gestation (preterm), and 6% of babies had severe perinatal morbidity. There were no
maternal deaths in this group, but there were still 30 cases of eclampsia.
In the HYPITAT (induction of labour versus expectant monitoring for gestational hypertension or mild
pre-eclampsia after 36 weeks’ gestation) I trial,29 women with PE (33%) and gestational hypertension
(66%) were randomised to delivery or conservative care after 37 weeks’ gestation. In the expectant
management group, 67% of women laboured spontaneously. In the study, the primary outcome was
defined as a composite measure of poor maternal outcome consisting of several conditions. Of women
who were randomised, 117 (31%) allocated to induction of labour developed poor maternal outcome
compared with 166 (44%) allocated to expectant monitoring [relative risk (RR) 0.71, 95% CI 0.59 to 0.86;
p < 0.0001]. No cases of maternal or neonatal death or eclampsia were recorded. They decided to include
progression to severe hypertension (systolic BP of > 170 mmHg or diastolic BP of > 110 mmHg on one
occasion) in their composite outcome because this disease is associated with severe maternal morbidity
(such as eclampsia, pulmonary oedema, cerebral encephalopathy or haemorrhage) and this was their
predominant component of the composite outcome. When the results of this trial are explored, the RR
of the composite adverse outcome for women with gestational hypertension (no proteinuria) is 31%
[induction of labour (IOL)] vs. 38% (expectant); RR 0.81, 95% CI 0.63 to 1.03), suggesting that immediate
delivery does not confer significant clinical benefit when proteinuria is not present. For the PE group, it was
33% (IOL) versus 54% (expectant) (RR 0.61, 95% CI 0.45 to 0.82). This supports the view that a good
‘rule-out’ test for proteinuria can identify a group of women with hypertension in pregnancy who can be
offered conservative management after 37 weeks of gestation with a high probability of spontaneous
labour. An interventional approach after 37 weeks of gestation (as advocated by current NICE guidelines)
has not been reported to significantly increase or decrease caesarean section rates.29
Our study highlights major variations in clinical management of severe PE in the UK. Only 32% of women
who met the NICE criteria for severe disease were managed in accordance with NICE’s ‘severe PE’
guidelines, and 11% of women were managed by clinicians as having severe disease when they did not
met the NICE definition. Within the group managed for severe PE by clinicians, 31 women (16%) did not
receive magnesium sulphate prophylaxis. Furthermore, 13 women (7%) received magnesium sulphate
prophylaxis but no other aspect of a severe PE management algorithm. No woman received magnesium
sulphate for fetal neuroprotection alone; therefore, this does not account for its use in isolation. The NICE
CG1071 states that the clinician should give magnesium sulphate if a women ‘has or previously had an
eclamptic fit’ and consider it if birth is planned within 24 hours and for other reasons. This is presumably
why 16% of women with severe PE (clinician diagnosis) did not receive it as prophylaxis.
The prevalence of adverse perinatal outcome was significantly more likely if severe PE was present.
However, it was not confined to those with severe disease. For those with severe disease, according to
NICE, the prevalence of adverse perinatal outcome was 8% versus 5% in those with non-severe disease
(p = 0.033) and for those whom the clinicians treated as having severe disease the prevalence of adverse
perinatal outcome was 15% versus 4% of those with non-severe disease (p ≤ 0.001). This almost certainly
reflects the clinician’s appreciation of the fetus’ condition as part of their assessment of severity, whereas
the NICE definition does not. In the HYPITAT I trial,29 in which a similar composite neonatal outcome was
reported, recruitment was restricted to > 36 weeks of pregnancy and their overall rate of occurrence
was 7%, and this was not influenced by immediate delivery or conservative care (6% vs. 8%).
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It is clear that the definition of severe PE in NICE’s CG1071 is very broad and includes the presence of
symptoms with only moderate hypertension and proteinuria. It states:
If considering magnesium sulphate* treatment, use the following as features of severe PE:
l severe hypertension and proteinuria or
l mild or moderate hypertension and proteinuria with one or more of the following:
¢ symptoms of severe headache
¢ problems with vision, such as blurring or flashing before the eyes
¢ severe pain just below the ribs or vomiting
¢ papilloedema
¢ signs of clonus (≥ 3 beats)
¢ liver tenderness
¢ HELLP syndrome
¢ platelet count falling to below 100 × 109 per litre
¢ abnormal liver enzymes (ALT or AST rising to above 70 iu/litre).
National Institute for Health and Clinical Excellence (2010) Hypertension in Pregnancy: The
Management of Hypertensive Disorders during Pregnancy. Available from: www.nice.org.uk/guidance/
cg107.1 NICE guidance is prepared for the National Health Service in England, and is subject to regular
review and may be updated or withdrawn. NICE has not checked the use of its content in this article
to confirm that it accurately reflects the NICE publication from which it is taken. Copyright © 2017
National Institute for Health and Care Excellence. All rights reserved.
From the study population, we found that 339 out of 417 women (81%) with severe PE (NICE definition)
had severe hypertension; therefore, the relatively common reporting of symptoms that can be difficult to
quantify did not really cause the high prevalence of severe PE. Severe hypertension at recruitment was rare.
This is likely to account for the high prevalence of severe disease according to this definition. Management
guidelines and algorithms mandate for senior multidisciplinary staff to be consulted regarding further
management of these women and it is possible that this seniority (and presumably experience) results in
fewer women being managed using severe PE care pathways.
In the HYPITAT I trial,29 when they changed the definition of severe hypertension from a BP of > 170/
110 mmHg on one occasion to a BP of > 170/110 mmHg on two occasions 6 hours apart, the prevalence
dropped from 38% to 19%. When severe disease is defined by an isolated recording of BP above a certain
threshold, prevalence will be significantly affected by the choice of threshold and be much higher with
definitions such as that of NICE, in which the threshold is 160 mmHg systolic and 110 mmHg diastolic.
In the HYPITAT II trial,30 the progression to severe PE was defined as diastolic BP of ≥ 110 mmHg despite
medication or systolic BP of ≥ 170 mmHg despite medication. Despite the study population being between
34 and 37 weeks’ gestation [a period during which PE is generally held to be higher risk or more severe
than at > 37 weeks’ gestation (HYPITAT I)] the trial found that the composite adverse maternal outcome
occurred in only 4 out of 352 women (1.1%) allocated to immediate delivery, compared with 11 out
of 351 women (3.1%) allocated to expectant monitoring (RR 0.36, 95% CI 0.12 to 1.11; p = 0.069).
This non-significant result could well have been because of their stricter definition of severe hypertension
and hence lower adverse outcome rate. They also found that respiratory distress syndrome was diagnosed
in 20 out of 352 neonates (5.7%) in the immediate delivery group, compared with 6 out of 351 (1.7%)
neonates in the expectant monitoring group (RR 3.3, 95% CI 1.4 to 8.2; p = 0.005). The authors conclude
that, for women with non-severe hypertensive disorders at 34–37 weeks’ gestation, immediate delivery
significantly increases the risk of neonatal respiratory distress syndrome; therefore, routine immediate
delivery does not seem justified and a strategy of expectant monitoring until the clinical situation
deteriorates can be considered.
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The majority of adverse perinatal outcomes (34/62, 55%) occurred in women who clinicians had decided
did not require severe PE management. Whether or not the more liberal use of management algorithms
and magnesium sulphate could reduce this is addressed in Recommendations for future research.
We have found that when the definition of severe hypertension is ‘less strict’ the prevalence of either severe
PE or a composite adverse maternal outcome will be high and others have also reported this. Our data
strongly suggest that clinicians will interpret clinical data and trial results based on experience and that
recommendations to change practice to minimise less clinically relevant end points may not be implemented
universally. We believe that this finding should be explored further in a formal qualitative study.
Urine testing: spot protein–creatinine ratio and spot
albumin–creatinine ratio
We set out to assess the diagnostic or predictive accuracy of the SPCR and SACR tests. The SPCR test was
performed both locally (in the recruiting hospital) and then, to minimise laboratory variation, all samples
were retested in a central ‘reference’ laboratory using two different assays for urine protein, BZC (the most
commonly employed assay) and PGR assays.
From ROC curve comparison there is minimal difference between assays tested and, although the SACR
test had a statistically significantly higher area under ROC, it is not likely that the small improvement offers
significant clinical benefits. When tested at prespecified cut-off points, all tests have very high sensitivities
but poor specificities. However, as ‘rule-out’ tests, the high sensitivities and low LR–s (≤ 0.1) mean that
they are of diagnostic value (Table 14).
The thresholds that we prespecified in the trial protocol were based on NICE’s CG1071 proteinuria
thresholds for proteinuria and the thresholds from Waugh et al.16 for albuminuria in previous work.
In non-obstetric practice, in which albuminuria is routinely utilised, a threshold of 3.5 mg/mmol is used to
delineate a positive result.23
Spot protein–creatinine ratio testing at different thresholds did not demonstrate a more discriminatory
threshold to predict severe PE than that recommended in NICE’s CG1071 of 30 mg/mmol.
Different thresholds for SACR suggest that diagnostic performance equivalent to 30 mg/mmol of SPCR is
achieved with a cut-off point level of 8 mg/mmol. This observation is further discussed in recommendations
for future research.
Other groups have suggested that SPCR testing offers improvement over conventional urine dipstick
testing for proteinuria alone.31 We tested the accuracy of the recruitment dipstick (read on an automated
reader). The accuracy of the urine dipstick is worse with a significantly lower specificity (20% vs. 57%;
p < 0.0001). The comparative performances are illustrated in Table 14. Waugh et al.16 has previously
shown that automated dipstick readers are significantly more predictive than the visual interpretation of
the same dipsticks. These results therefore suggest that visually read urine dipsticks should not be
advocated for proteinuria screening in pregnancy.
Previous individual studies that have subsequently been subject to meta-analysis have compared the
accuracy of urine dipsticks, SPCR and SACR in the prediction of significant proteinuria measured by a
24-hour urine protein.16,31–33
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We again observed that all SPCR assays and SACR perform similarly, with the reference laboratory testing
for SACR offering significant differences compared with the SPCR but with very poor specificity (23%).
ROC curve areas summarised in Table 24 confirm the tests are all very similar in terms of performance.
When the tests (SPCR and SACR) are utilised to predict the reference standard of clinician diagnosis of
severe PE (see Table 31), sensitivity falls for all SPCR tests from 93–95% to 84–85%. Sensitivity for SACR is
maintained but specificity is very low at 16%.
There is no improvement seen in using 24-hour urine samples and SPCR testing, and dipstick testing alone
had the lowest specificity of any test at 13% (see Table 31).
Receiver operating characteristic curves, when overlain, demonstrated that diagnostic accuracy was much
poorer than for the NICE definition of PE as a reference standard. Again, the areas under the reference
laboratory assay tests were significantly greater than the local laboratory assay but the differences, while
statistically significant, are unlikely to be of clinical utility and may just demonstrate the small effect of
interlaboratory assay error.
Very similar results were found when the prediction of adverse perinatal outcome was tested. Sensitivities
were generally poor (69–79%), but the SACR test at the prespecified threshold of 2 mg/mmol was the
exception at 94%. Although better than the SPCR tests for sensitivity, it also had a lower specificity
(14% vs. 35–39%).
We also analysed the spot urine samples collected immediately prior to delivery to allow for secondary
analysis of both the incremental increase in proteinuria between recruitment and delivery and the
maximum level of proteinuria achieved prior to delivery. Even acknowledging that these samples proved
difficult to collect with the unplanned onset of labour, 530 samples could be included in an analysable
data set. Neither the incremental increase nor the maximum proteinuria level offered any improvement
over the original recruitment sample in the prediction of adverse perinatal outcomes.
When all of these analyses were repeated on a subgroup of women who all had 1+ proteinuria on
recruitment dipstick assessment, there was no change in the diagnostic accuracy of the tests.
We found, as have previous authors, a difference between the two protein assays compared during this
study. The proportion of women with > 300 mg/24 hours was higher using the PGR (55%) than the
BZC (50%) assay. Consequently, severe PE was diagnosed 5% more often. If this assay was used as the
reference standard to diagnose PE and the analysis was repeated, the results were again very similar with
all three SPCR assays having high sensitivities but much lower specificities and SACR being statistically
better but with only marginal differences to confer any clinical advantage. It appears, from this study,
that differences do exist between proteinuria assays and, as such, they by definition can influence the
prevalence of PE (when used in the definition) by a small amount (5% in this study and up to 45% in
previous studies).8,34 There does not seem to be any difference in diagnostic accuracy related to the
prediction of adverse maternal or perinatal outcomes. This is again mentioned in recommendations for
future research.
When the two assays are compared using a Bland–Altman plot there is clearly a non-linear relationship.
Pragmatically, given that the threshold for diagnosing PE is 300 mg/l and most samples will fall between 0
and 2000 g/l, we have shown that up to approximately 1200 g/l the PGR assay is generally higher than the
BZC assay (up to 100 mg/l) and hence PE is diagnosed more frequently and potentially ‘overdiagnosed’.
Above 1200 mg/l, the PGR assay value is typically smaller but clearly PE will be diagnosed anyway as the
differences are small.
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Economic evaluation
The economic evaluation was designed to compare the cost-effectiveness of six alternative tests used to
identify severe PE in pregnant women with gestational hypertension: the central laboratory’s SACR test,
the central laboratory’s SPCR test (using the BZC or PGR assays), 24-hour urine collection (using the
BZC or PGR assays) and dipstick test only against the local laboratory’s SPCR test, which was considered
as the standard care comparator. A modelling approach was undertaken by the authors to estimate the
incremental cost (from the perspective of the NHS) per QALY gained of each comparator test. The model
combined information on the diagnostic accuracy (i.e. sensitivity and specificity) of each test collected as
part of the clinical study with therapeutic pathways based on previously developed economic models
published by NICE in their hypertension in pregnancy CG1071 in 2010. These pathways were used to
model the effect of diagnostic errors (false positives and negatives) on the cost of neonatal and maternal
care, as well as QALY losses resulting from premature death of the mother or baby, or both.
The base-case analysis demonstrated that the local laboratory’s SPCR test generated 52.39 maternal and
neonatal QALYs over a lifetime at cost of £6621. Four strategies [central laboratory’s SACR test, dipstick
test only, 24-hour urine collection (as measured via the BZC assay) and central laboratory’s SPCR test
(as measured via the BZC assay)] were non-dominated compared with the baseline comparator (did not
have a lower effectiveness and higher cost), although the dipstick test only was dominated by at least one
other strategy. The differences in cost and QALYs across alternative tests were small, which is a reflection of
the small differences in the accuracy of each test reported in the statistical analysis. When an incremental
cost-effectiveness analysis was performed, it confirmed that the effectiveness of all the comparators was
very similar, with only 0.04 QALYs between the best- and worst-performing tests. Cost differences were
greater, with dipstick alone costing £66 more than the local laboratory’s SPCR test. Although this result may
suggest that the SPCR test could be used alone, it must be remembered that only women with trace or
greater of proteinuria on the dipstick have been included in this study and the impact of reverting to a
SPCR-only strategy cannot be assessed, as women with ‘no proteinuria’ on dipstick have not been included.
The central laboratory’s SACR test was the most effective strategy (52.42 QALYs gained) with an ICER of
£1502 per QALY in the base-case scenario and £1255 per QALY in the PSA, although the 95% CI crossed
zero (–£6124 to £8635) as a result of significant uncertainty and a small difference in incremental cost and
QALYs. Despite this wide range, however, the upper bound of the CI was below the NICE threshold for
acceptability of new health-care technology, meaning that the central laboratory’s SACR test was likely to
be a cost-effective choice. A deterministic analysis designed to test the effect of changes in model inputs
on NMB, assuming a WTP of £20,000 per QALY, showed that the central laboratory’s SACR test remained
the optimal strategy when model parameters were varied over pre-assigned ranges. A cost-effectiveness
acceptability curve constructed using the PSA output demonstrated that the central laboratory’s SACR
test had a 100% probability of being the most cost-effective option at the standard range of WTP of
£20,000–30,000 per QALY recommended by NICE.
This cost-effectiveness study employed a modelling approach to complement within-study data collection,
which did not observe the cost and QALY outcomes of each test because of its prospective cohort design.
The authors adapted a previously validated model pathway designed by NICE that used evidence from
previous studies of maternal and neonatal care in gestational hypertension and PE in combination with
expert opinion. As such, the therapeutic pathways that were used to determine cost and QALY outcomes
in the model accurately reflect current practice in maternal and neonatal care in the presence of these
conditions. Information on LOS in maternal and neonatal units collected prospectively during the study
contributed to accurate estimates of the cost of intensive care in severe PE that were representative of the
study population.
The modelling analysis was restricted to the perinatal period and did not include the effect of PE on
resource use and quality of life in later years of life. The cost estimates produced in the model were
potentially insensitive to long-term cost effects of diagnostic errors, which is a limitation of the model.
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QALY estimates were based on life-years lost as a result of premature maternal or neonatal death, which is
a simplification that may have underestimated the true impact of false negatives on patient utility.
The results of the economic analysis indicate the potential superior cost-effectiveness of the SACR test over
other tests as a tool to diagnose severe PE in women with gestational hypertension. This study contributed
to the evidence base on the relative value of alternative diagnostic tests for PE in antenatal care. Given
the high cost of maternal and neonatal intensive care, the use of cost-effective diagnostic tools is required
for timely identification of severe PE, prevention of unnecessary hospital admission and premature deaths.
An economic evaluation alongside a randomised study is necessary in order to produce conclusive estimates
of the relative cost-effectiveness of alternative testing methods for severe PE.
Conclusions
From the results of this study we can draw the following conclusions:
1. The SACR test has marginally better diagnostic accuracy characteristics than the SPCR test when
predicting severe PE according to NICE’s CG1071 definitions.
2. All four tests could be used as rule-out tests for the NICE definition of severe PE, in that if there is a
negative test result, the odds of severe PE are considerably reduced (tenfold or more) compared with
the odds in the target population as a whole before the test is performed.
3. The collection of a 24-hour urine sample confers no additional value over a spot urine sample to
quantify proteinuria in women with hypertension in pregnancy.
4. The threshold level of SPCR that performs best for the prediction of severe PE is the current threshold
of 30 mg/mmol.
5. The threshold level of SACR that is equivalent to this, in terms of clinical accuracy, is 8 mg/mmol.
6. Urine dipstick testing without laboratory testing of SPCR or SACR performs poorly as a predictive
strategy for either severe PE or adverse perinatal outcomes.
7. The measurement of ‘maximum proteinuria’ or a ‘rise in proteinuria’ confers no advantage in the
prediction of severe PE or adverse perinatal outcomes in hypertensive pregnancies.
8. Biochemical assays for proteinuria are not universal and as such some assays (e.g. PGR) will
overdiagnose PE compared with the BZC assay by at least 5%.
9. The SACR test was deemed to have a 100% probability of being the most cost-effective option at the
standard WTP threshold of £20,000–30,000 per QALY as recommended by NICE.
10. Clinicians continue to plan care (and interpret results) in an inconsistent manner when caring for
women with severe PE.
11. The non-uniform application of NICE’s CG1071 severe PE management algorithms and definitions by
clinicians does not confer any additional benefits in reducing the number of women who will have
adverse perinatal outcomes.
Implications for clinical practice
1. Evidence would suggest that all proteinuria assessments should be performed by an initial dipstick
screening test read on an automated dipstick reader, and for all non-negative tests a SACR test should
be considered. In the absence of SACR being available, SPCR could be used as an alternative.
2. Given the intermethod/laboratory variability of protein assays demonstrated, all ‘protein’ tests should be
viewed with extreme caution and consideration should be given to a urine albumin assay being
employed for future definitions.
3. Clinically significant proteinuria should remain defined at a level of 8 mg/mmol measured by the SACR
test or 30 mg/mmol measured by the SPCR test.
4. The evidence from this clinical study does not support the recommendation of 24-hour urine sample
collection in hypertensive pregnant women.
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5. Once the SPCR test is confirmed to be > 30 mg/mmol, no further proteinuria measurements are
required during hypertensive pregnancy.
6. Whenever possible, proteinuria measurements should be by a single (accepted as standard) assay.
When this is not a BZC assay, clinicians should be aware that some assays can overdiagnose proteinuria
and, hence, PE.
7. In the presence of hypertension in pregnancy without proteinuria, the progression to severe maternal
disease is unlikely (7% for SPCR and 2% for SACR). Adverse maternal and perinatal outcomes do occur
and all women with gestational hypertension should be closely monitored.
Recommendations for future research
1. Spot albumin–creatinine ratio at a threshold of 8 mg/mmol should be studied as a ‘rule-out’ test of
proteinuria and for the prediction of severe PE.
2. The reasons for the wide variation in clinician management of severe PE despite NICE guidelines should
be explored through a qualitative study. This would have implications for the wider medical community.
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Appendix 1 The DAPPA trial timeline and
key milestones
TABLE 81 The DAPPA trial timeline and key milestones
Date Milestone
4 December 2012 Research and development approval granted by Newcastle
upon Tyne Hospitals (sponsor)
5 December 2012 Minor amendment 1 (addition of three new sites, change
of database to MedSciNet and other minor clarifications)
26 February 2013 Minor amendment 2 (change of principal investigator at
St Bartholomew's Hospital site)
March 2013 One patient recruited at Royal Victoria Infirmary, Newcastle
upon Tyne
1–7 July 2013 Substantial amendment (creation of study poster for
maternity units)
6 September 2013 Trial Steering Committee meeting
11 September 2013 Research Ethics Committee annual progress
report submitted
2 October 2013 Monitoring Project review meeting, HTA, London
1 April 2014 Minor amendment 3 (amendment to general practitioner letter)
7 April 2014 Trial Steering Committee meeting
30 June 2014 Trial Steering Committee meeting
3 September 2014 Monitoring project review meeting, HTA, London
September 2014 Change of trial manager following resignation
1 October 2014 Trial Steering Committee meeting
8 January 2015 Minor amendment 4 (translation of documents into Urdu
and Polish)
3 February 2015 Research Ethics Committee annual progress report submitted
19 June 2015 Substantial amendment 2 (8-month extension, reduce
recruitment target, increase funding, change staffing,
central monitoring, change to laboratory testing and
updates to protocol)
16 October 2015 Trial Steering Committee meeting
3 November 2015 Research Ethics Committee annual progress report submitted
30 November 2015 End of patient recruitment
5 January 2016 All samples shipped from sites to Kent laboratory
18 May 2016 Kent laboratory analysis complete, data entered
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TABLE 81 The DAPPA trial timeline and key milestones (continued )
Date Milestone
25 May 2016 Research Ethics Committee end of study report submitted
and acknowledged
26 May 2016 MedSciNet database closed to data entry and passed
to statisticians
2 June 2016 MedSciNet database sent for archiving
11 September 2016 HTA final report submitted
March 2013, September 2013, March 2014, July 2014,
August 2014, March 2015, September 2015 and April 2016
HTA progress reports submitted
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